Kadmon (KDMN) 10-Q 9 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 05, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Trading Symbol	kdmn
Entity Registrant Name	Kadmon Holdings, Inc.
Entity Central Index Key	1,557,142
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		113,130,817
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Small Business	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 113,351	$ 67,517
Accounts receivable, net	972	325
Accounts receivable from affiliates	7	861
Inventories, net	1,063	201
Prepaid expenses and other current assets	2,225	1,109
Total current assets	117,618	70,013
Fixed assets, net	4,027	4,292
Goodwill	3,580	3,580
Restricted cash	2,116	2,116
Investment, equity securities	48,072
Investment, at cost	2,300	3,542
Other noncurrent assets	2	9
Total assets	177,715	83,552
Current liabilities:
Accounts payable	6,946	8,008
Accrued expenses	9,514	8,577
Deferred revenue		4,400
Fair market value of financial instruments - current	1,247	1,952
Secured term debt - current		33,707
Total current liabilities	17,707	56,644
Deferred revenue		19,617
Deferred rent	4,294	4,347
Deferred tax liability	377	939
Other long term liabilities	69	247
Secured term debt – net of current portion and discount	27,386
Total liabilities	49,833	81,794
Commitments and contingencies (Note 14 and 15)
Stockholders’ equity:
Convertible Preferred Stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2018 and December 31, 2017; 30,000 shares issued and outstanding at September 30, 2018 and December 31, 2017	41,716	40,220
Common Stock, $0.001 par value; 200,000,000 shares authorized at September 30, 2018 and December 31, 2017; 113,101,776 and 78,643,954 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	113	79
Additional paid-in capital	313,664	198,856
Accumulated deficit	(227,611)	(237,397)
Total stockholders’ equity	127,882	1,758
Total liabilities and stockholders’ equity	$ 177,715	$ 83,552

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	113,101,776	78,643,954
Common stock, shares outstanding	113,101,776	78,643,954
Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	30,000	30,000
Preferred stock, shares outstanding	30,000	30,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues
Total revenue	$ 372	$ 2,277	$ 1,164	$ 10,800
Cost of sales	59	277	361	1,110
Write-down of inventory	20	933	265	1,676
Gross profit	293	1,067	538	8,014
Operating expenses:
Research and development	11,918	11,775	31,876	30,278
Selling, general and administrative	9,668	9,121	26,730	29,141
Total operating expenses	21,586	20,896	58,606	59,419
Loss from operations	(21,293)	(19,829)	(58,068)	(51,405)
Other expense (income) :
Interest income	(534)	(11)	(742)	(44)
Interest expense	877	1,469	3,680	4,499
Change in fair value of financial instruments	(198)	(1,340)	(802)	(2,066)
Loss on equity method investment		1,750	1,242	7,479
Unrealized gain on equity securities	(7,564)		(48,072)
Other income	(75)	6	(77)	(5)
Total other expense (income)	(7,494)	1,874	(44,771)	9,863
Loss before income tax	(13,799)	(21,703)	(13,297)	(61,268)
Income tax expense (benefit)			(562)	316
Net loss	(13,799)	(21,703)	(12,735)	(61,584)
Deemed dividend on convertible preferred stock	515	490	1,496	1,428
Net loss attributable to common stockholders	$ (14,314)	$ (22,193)	$ (14,231)	$ (63,012)
Basic and diluted net loss per share of common stock	$ (0.13)	$ (0.42)	$ (0.15)	$ (1.25)
Weighted average basic and diluted shares of common stock outstanding	113,101,776	52,572,880	92,378,205	50,331,163
License and Other Revenue [Member]
Revenues
Total revenue	$ 174	$ 1,241	$ 531	$ 5,730
Net Sales [Member]
Revenues
Total revenue	$ 198	$ 1,036	$ 633	$ 5,070

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2017	$ 40,220	$ 79	$ 198,856	$ (237,397)	$ 1,758
Balance, Shares at Dec. 31, 2017	30,000	78,643,954
Share-based compensation expense			2,572		2,572
Common stock issued for warrant exercises			26		26
Common stock issued for warrant exercises, shares		8,195
Beneficial conversion feature on convertible preferred stock	$ 98			(98)
Accretion of dividends on convertible preferred stock	392			(392)
Net income (loss)				(20,441)	(20,441)
Balance at Mar. 31, 2018	$ 40,710	$ 79	201,454	(234,311)	7,932
Balance, Shares at Mar. 31, 2018	30,000	78,652,149
Balance at Dec. 31, 2017	$ 40,220	$ 79	198,856	(237,397)	1,758
Balance, Shares at Dec. 31, 2017	30,000	78,643,954
Beneficial conversion feature on convertible preferred stock					299
Accretion of dividends on convertible preferred stock					1,197
Net income (loss)					(12,735)
Balance at Sep. 30, 2018	$ 41,716	$ 113	313,664	(227,611)	127,882
Balance, Shares at Sep. 30, 2018	30,000	113,101,776
Balance at Mar. 31, 2018	$ 40,710	$ 79	201,454	(234,311)	7,932
Balance, Shares at Mar. 31, 2018	30,000	78,652,149
Share-based compensation expense			3,023		3,023
Common stock issued in public offering, net		$ 34	105,727		105,761
Common stock issued in public offering, net, shares		34,303,030
Common stock issued for warrant exercises			562		562
Common stock issued for warrant exercises, shares		123,639
Common stock issued under ESPP plan			65		65
Common stock issued under ESPP plan, shares		22,958
Cumulative effect of change in accounting principle - ASC 606 adoption at Mar. 31, 2018				24,017	24,017
Beneficial conversion feature on convertible preferred stock	$ 98			(98)
Accretion of dividends on convertible preferred stock	393			(393)
Net income (loss)				21,505	21,505
Balance at Jun. 30, 2018	$ 41,201	$ 113	310,831	(213,297)	138,848
Balance, Shares at Jun. 30, 2018	30,000	113,101,776
Share-based compensation expense			2,833		2,833
Beneficial conversion feature on convertible preferred stock	$ 103			(103)
Accretion of dividends on convertible preferred stock	412			(412)
Net income (loss)				(13,799)	(13,799)
Balance at Sep. 30, 2018	$ 41,716	$ 113	$ 313,664	$ (227,611)	$ 127,882
Balance, Shares at Sep. 30, 2018	30,000	113,101,776

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (12,735)	$ (61,584)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization of fixed assets	1,105	1,389
Write-down of inventory	265	1,676
Amortization of deferred financing costs	228	382
Amortization of debt discount	1,077	1,721
Amortization of debt premium	(345)	(376)
Share-based compensation	8,428	10,558
Change in fair value of financial instruments	(802)	(2,066)
Loss on equity method investment	1,242	7,479
Unrealized gain on equity securities	(48,072)
Deferred tax liability	(562)
Changes in operating assets and liabilities:
Accounts receivable, net	207	273
Inventories, net	(1,127)	62
Prepaid expenses and other assets	(1,109)	(766)
Accounts payable	(1,072)	4,497
Accrued expenses, other liabilities and deferred rent	686	(5,800)
Deferred revenue		(3,300)
Net cash used in operating activities	(52,586)	(45,855)
Cash flows from investing activities:
Purchases of fixed assets	(811)	(474)
Net cash used in investing activities	(811)	(474)
Cash flows from financing activities:
Proceeds from issuance of common stock and warrants, net	105,761	83,861
Payment of financing costs	(596)	(20)
Principal payments on secured term debt	(6,574)
Proceeds from issuance of ESPP shares	65
Proceeds from exercise of warrants	575
Net cash provided by financing activities	99,231	83,841
Net increase in cash, cash equivalents and restricted cash	45,834	37,512
Cash, cash equivalents and restricted cash, beginning of period	69,633	38,209
Cash, cash equivalents and restricted cash, end of period	115,467	75,721
Components of cash, cash equivalents, and restricted cash
Total cash, cash equivalents, and restricted cash	69,633	38,209
Supplemental cash flow disclosures:
Cash paid for interest	2,750	2,756
Cash paid for taxes		353
Non-cash investing and financing activities:
Fair value of warrants issued in private placement		1,651
Fair value of modification to lender warrants	111	908
Unpaid financing/offering costs	29	208
Unpaid fixed asset purchases		558
Beneficial conversion feature on convertible preferred stock	299	286
Accretion of dividends on convertible preferred stock	1,197	$ 1,142
Cumulative effect of change in accounting principle - ASC 606 adoption	$ 24,017

Organization

Organization	9 Months Ended
	Sep. 30, 2018
Organization [Abstract]
Organization	1. Organization Nature of Business Kadmon Holdings, Inc. (together with its subsidiaries, “Kadmon” or “Company”) is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical needs, with a near-term clinical focus on inflammatory and fibrotic diseases. The Company leverages its multi ‑disciplinary research and clinical development team to identify and pursue a diverse portfolio of novel product candidates, both through in-licensing products and employing its small molecule and biologics platforms. By retaining global commercial rights to its lead product candidates, the Company believes that it has the ability to develop these candidates while maintaining flexibility for commercial and licensing arrangements. The Company expects to continue to progress its clinical candidates and have further clinical trial data to report throughout 2018 and 2019. Liquidity The Company had an accumulated deficit of $227.6 million and working capital of $99.9 million at September 30, 2018 . The Company maintained cash and cash equivalents of $113.4 million at September 30, 2018 . In June 2018, the Company raised $113.2 million ( $105.8 million net of $7.4 million of underwriting discounts and other offering expenses payable by the Company) from the issuance of 34,303,030 shares of common stock at a price of $3.30 per share (“2018 Public Offering”). The Company’s existing cash and cash equivalents is expected to enable it to advance its planned Phase 2 clinical studies for KD025 and tesevatinib, advance certain of its other pipeline product candidates and provide for other working capital purposes . The Company believes its cash and cash equivalents balance at September 30, 2018, when considered with its forecasted cash expenditures, continues to alleviate the substantial doubt about its ability to continue as a going concern. On June 12, 2018, the Company entered into the fourth amendment to the 2015 Credit Agreement (the “Fourth Amendment”) (Note 5). Pursuant to the Fourth Amendment, the maturity date of the 2015 Credit Agreement was extended to August 31, 2018 (the “Extension Period”). The Company repaid $4.7 million of the outstanding principal on June 18, 2018, representing all amounts due under the 2015 Credit Agreement to GoldenTree Credit Opportunities, LP, GoldenTree Credit Opportunities, Ltd, GoldenTree Insurance Fund Series Interests of the SALI Multi-Series Fund, LP, GT NM, LP, and San Bernardino County Employees’ Retirement Association. All other material terms of the 2015 Credit Agreement remained the same during the Extension Period, including a minimum liquidity covenant. On August 15, 2018, the Company entered into the fifth amendment to the 2015 Credit Agreement (the “Fifth Amendment”) (Note 5). Pursuant to the Fifth Amendment, the maturity date of the Credit Agreement was extended to July 1, 2020 and principal payments have been deferred until January 31, 2020. Beginning on January 31, 2020, equal principal payments of $750,000 per month will be due until the maturity date. Additionally, the parties amended certain covenants under the 2015 Credit Agreement to require the Company to meet certain developmental milestones by December 31, 2019. All other material terms of the 2015 Credit Agreement remain the same, including a minimum liquidity covenant. No assurances can be given that the Company will be able to comply with these covenants or that the Company will be able to amend the 2015 Credit Agreement to further extend the maturity date or refinance this debt on or before the maturity date. The Company has not established a source of revenue sufficient to cover its operating costs, and as such, has been dependent on funding operations through the issuance of debt and sale of equity securities. The Company expects to incur further losses over the next several years as it develops its business. The Company anticipates that it will need additional capital to fund its continued operations and remain in compliance with its debt covenants. T he Company has no commitments for any additional financing, and there can be no assurance that, if needed, additional capital will be available to the Company on commercially acceptable terms or at all.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The Company operates in one segment considering the nature of the Company’s products and services, class of customers, methods used to distribute the products and the regulatory environment in which the Company operates. Principles of Consolidation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The consolidated financial statements include the accounts of Kadmon Holdings, Inc. and its domestic and international subsidiaries, all of which are wholly owned. Interim Financial Statements The accompanying financial statements have been prepared in accordance with GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In management’s opinion, the financial statements include all adjustments (consisting of normal recurring accruals) necessary in order to make the financial statements not misleading. Operating results for the three and nine months ended September 30, 2018 are not necessarily indicative of the final results that may be expected for the year ended December 31, 2018. These unaudited financial statements should be read in conjunction with the audited financial statements in Item 15 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Actual results could differ from those estimates. Critical accounting policies The Company’s significant accounting policies are disclosed in the audited financial statements included in Item 8 of the Annual Report on Form 10-K as of and for the year ended December 31, 2017. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies, other than those described below. Investment in Equity Securities Equity securities consist of investments in common stock of companies traded on public markets (Note 10). These shares are carried on the Company’s balance sheet at fair value based on the closing price of the shares owned on the last trading day before the balance sheet of this report. Fluctutations in the underlying bid price of the shares result in unrealized gains or losses. In accordance with FASB ASC 321, Investments – Equity Securities (“ASC 321”), the Company recognizes these fluctuations in value as other expense (income). For investments sold, the Company recognizes the gains and losses attributable to these investments as realized gains or losses in other expense (income). Revenue Recognition The Company adopted FASB ASC 606, Revenue from Contracts with Customers (“ASC 606”), on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption – i.e., by recognizing the cumulative effect of initially applying ASC 606 as an adjustment to the opening balance of stockholders’ equity at January 1, 2018. For contracts that were modified before the effective date, the Company reflected the aggregate effect of all modifications when identifying performance obligations and allocating transaction price in accordance with practical expedient ASC 606-10-65-1-(f)-4. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (“ASC 605”), which is also referred to herein as the "previous guidance". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services and will provide financial statement readers with enhanced disclosures. Therefore, the comparative information prior to January 1, 2018 has not been adjusted and continues to be reported under ASC 605. The details of significant changes and quantitative impact of the changes are set out below. The Company recognizes revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation. Disaggregation of Revenue The following table summarizes revenue from contracts with customers for the three and nine months ended September 30, 2018 (in thousands):    Three Months Ended Nine Months Ended  September 30, 2018 September 30, 2018  Product sales $ 198 $ 633  Other revenue 174 531  Total revenue $ 372 $ 1,164 Product Sales The Company markets a portfolio of branded and generic ribavirin products used as part of a combination treatment for chronic HCV infection (Ribasphere RibaPak and Ribasphere) and also distributes products in a variety of other therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington’s disease. These contracts typically include a single promise to deliver a fixed amount of product to the customer with payment due within 30 days of shipment. Revenues are recognized when control of the promised goods is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods. As is typical in the pharmaceutical industry, gross product sales are subject to a variety of deductions, primarily representing rebates, chargebacks, returns, and discounts to government agencies, wholesalers, and managed care organizations. These deductions represent management’s best estimates of the related reserves and, as such, judgment is required when estimating the impact of these sales deductions on gross sales for a reporting period. If estimates are not representative of the actual future settlement, results could be materially affected. Other Revenue The other revenue generated by the Company is primarily related to the transition services agreement and sublease agreement with MeiraGTx Holdings plc (“MeiraGTx”) (Note 10) . The Company performed various professional services under the transition services agreement that support MeiraGTx. The Company recognizes revenue related to transition services and sublease agreements as they are performed. Contract Balances The timing of revenue recognition may differ from the timing of invoicing to customers. Accounts receivable are recorded at the invoiced amount, net of an allowance for doubtful accounts. A receivable is recognized in the period we deliver goods or provide services or when our right to consideration is unconditional. The Company has not recognized any assets for costs to obtain or fulfill a contract with a customer as of September 30, 2018 . Financial Statement Impact of Adopting ASC 606 The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers that were not completed as of January 1, 2018 was recorded as an adjustment to accumulated deficit as of the adoption date as shown in the following table (in thousands):   As Reported Adjustments Adjusted  December 31, AbbVie January 1,  2017 Agreement 2018  (unaudited) (unaudited)  Cash, cash equivalents, and restricted cash $ 69,633 $ $ 69,633  Accounts receivable, net 1,186 1,186  Inventories, net 201 201  Prepaid expenses and other current assets 1,109 1,109  Fixed assets, net 4,292 4,292  Goodwill 3,580 3,580  Investments at cost 3,542 3,542  Other noncurrent assets 9 9  Total assets $ 83,552 $ $ 83,552  Accounts payable and accrued expenses $ 16,585 $ $ 16,585  Fair market value of financial instruments - current 1,952 1,952  Secured term debt - current 33,707 33,707  Deferred revenue, current 4,400 (4,400) —  Deferred revenue, long term 19,617 (19,617) —  Other long term liabilities 5,533 5,533  Total liabilities 81,794 (24,017) 57,777  Common stock, preferred stock, and additional paid-in capital 239,155 239,155  Accumulated deficit (237,397) 24,017 (213,380)  Total stockholders’ equity 1,758 24,017 25,775  Total liabilities and stockholders’ equity $ 83,552 $ — $ 83,552 The year-end condensed balance sheet data was derived from audited consolidated financial statements, but does not include all disclosures required by GAAP. Commercial Partnership Agreement with AbbVie Inc. (“AbbVie”) On June 17, 2013, the Company entered into a series of agreements with AbbVie related to certain of the Company’s ribavirin products. Pursuant to an asset purchase agreement, as amended, the Company sold marketing authorizations and related assets for ribavirin in certain countries outside the United States. The Company received upfront payments totaling $64.0 million, and could have received additional contingent payments totaling $51.0 million based on the achievement of certain milestones. The Company did not earn any such milestones during the nine months ended September 30, 2018 . Of the $64.0 million upfront payments, $44.0 million was considered allocable to the domestic licensing arrangement and was recorded as deferred revenue to be recognized over the 10 year term of the agreement. The Company recognized $1.1 million and $3.3 million during the three and nine months ended September 30, 2017 , respectively. At December 31, 2017, $24.0 million was recorded as deferred revenue, of which $4.4 million was short ‑term. The Company is required to supply ribavirin products, maintain the marketing authorization for certain ribavirin products and maintain the intellectual property for Ribasphere and RibaPak through the term of the agreements ending December 31, 2020. The Company’s agreements with AbbVie provide AbbVie with access to various forms of intellectual property, as well as supply of product. Under the previous guidance, certain of the upfront payments under the agreements were considered allocable to a 10-year domestic license arrangement and, as a result, the associated revenue was previously deferred and recognized straight line over the life of the agreements. Under ASC 606, the Company has determined that two distinct performance obligations under the domestic license agreement exist, both of which are considered to be completed as of the date of adoption. No other material rights or enforceable rights or obligations exist under the AbbVie agreements. In conjunction with the January 1, 2018 adoption of ASC 606, the Company adjusted its accumulated deficit by $24.0 million, reflecting the recognition of $24.0 million of deferred revenue related to the domestic license agreement with AbbVie. Income Taxes The adoption of ASC 606 primarily resulted in an acceleration of revenue as of January 1, 2018, which in turn generated additional deferred tax liabilities that ultimately reduced the Company's net deferred tax asset position. As the Company fully reserves its net deferred tax assets in the jurisdictions impacted by the adoption of ASC 606, this impact was offset by a corresponding reduction to the valuation allowance. Impact of New Revenue Guidance on Financial Statement Line Items The following table compares the reported condensed consolidated balance sheet as of September 30, 2018 to the pro-forma amounts had the previous guidance been in effect (in thousands):   As Reported Balances without adoption of ASC 606  September 30, 2018 Adjustments September 30, 2018 December 31, 2017  (unaudited) (unaudited) (unaudited)  Cash, cash equivalents, and restricted cash $ 115,467 $ $ 115,467 $ 69,633  Accounts receivable, net 979 979 1,186  Inventories, net 1,063 1,063 201  Investment, equity securities 48,072 48,072 —  Prepaid expenses and other current assets 2,225 2,225 1,109  Fixed assets, net 4,027 4,027 4,292  Goodwill 3,580 3,580 3,580  Investment, at cost 2,300 2,300 3,542  Other noncurrent assets 2 2 9  Total assets $ 177,715 $ — $ 177,715 $ 83,552  Accounts payable and accrued expenses $ 16,460 $ $ 16,460 $ 16,585  Fair market value of financial instruments - current 1,247 1,247 1,952  Secured term debt - current — — 33,707  Deferred revenue, current — 4,400 4,400 4,400  Deferred revenue, long term — 16,317 16,317 19,617  Other long term liabilities 4,740 4,740 5,533  Secured term debt – net of current portion and discount 27,386 27,386 —  Total liabilities 49,833 20,717 70,550 81,794  Common stock, preferred stock, and additional paid-in capital 355,493 355,493 239,155  Accumulated deficit (227,611) (20,717) (248,328) (237,397)  Total stockholders’ equity (deficit) 127,882 (20,717) 107,165 1,758  Total liabilities and stockholders’ equity $ 177,715 $ — $ 177,715 $ 83,552 The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. Total reported liabilities were $20.7 million less than the pro-forma balance sheet, which assumes the Company had continued to recognize revenues under ASC 605 as of September 30, 2018 . This is due to the recognition of the deferred revenue related to the AbbVie agreement upon adoption of ASC 606. The following summarizes the significant changes on the Company’s condensed consolidated statement of operations for the three months ended September 30, 2018 as a result of the adoption of ASC 606 on January 1, 2018, which assumes the Company had continued to recognize revenues under ASC 605 (in thousands, except share and per share amounts):    As Reported Three Months Ended Balances without adoption of ASC 606 Three Months Ended  September 30, 2018 Adjustments September 30, 2018 September 30, 2017  (unaudited) (unaudited) (unaudited) (unaudited)  Net sales $ 198 $ $ 198 $ 1,036  License and other revenue 174 1,100 1,274 1,241  Total revenue 372 1,100 1,472 2,277  Cost of sales and write-down of inventory 79 79 1,210  Research and development 11,918 11,918 11,775  Selling, general and administrative 9,668 9,668 9,121  Total other expense (income) (7,494) (7,494) 1,874  Net income (loss) attributable to common stockholders $ (13,799) $ 1,100 $ (12,699) $ (21,703)  Deemed dividend on convertible preferred stock 515 515 490  Net income (loss) attributable to common stockholders $ (14,314) $ 1,100 $ (13,214) $ (22,193)   Basic and diluted net income (loss) per share of common stock $ (0.13) $ 0.01 $ (0.12) $ (0.42)  Weighted average basic and diluted shares of common stock outstanding 113,101,776 113,101,776 113,101,776 52,572,880 The following summarizes the significant changes on the Company’s condensed consolidated statement of operations for the nine months ended September 30, 2018 as a result of the adoption of ASC 606 on January 1, 2018, which assumes the Company had continued to recognize revenues under ASC 605 (in thousands, except share and per share amounts):    As Reported Nine Months Ended Balances without adoption of ASC 606 Nine Months Ended  September 30, 2018 Adjustments September 30, 2018 September 30, 2017  (unaudited) (unaudited) (unaudited) (unaudited)  Net sales $ 633 $ $ 633 $ 5,070  License and other revenue 531 3,300 3,831 5,730  Total revenue 1,164 3,300 4,464 10,800  Cost of sales and write-down of inventory 626 626 2,786  Research and development 31,876 31,876 30,278  Selling, general and administrative 26,730 26,730 29,141  Total other expense (income) (44,771) (44,771) 9,863  Income tax expense (benefit) (562) (562) 316  Net income (loss) attributable to common stockholders $ (12,735) $ 3,300 $ (9,435) $ (61,584)  Deemed dividend on convertible preferred stock 1,496 1,496 1,428  Net income (loss) attributable to common stockholders $ (14,231) $ 3,300 $ (10,931) $ (63,012)   Basic and diluted net income (loss) per share of common stock $ (0.15) $ 0.04 $ (0.11) $ (1.25)  Weighted average basic and diluted shares of common stock outstanding 92,378,205 92,378,205 92,378,205 50,331,163 The Company’s adoption of ASC 606 accelerated the recognition of revenue that was previously deferred under the AbbVie domestic license agreement, resulting in a cumulative effect adjustment to accumulated deficit on January 1, 2018. Therefore no further revenue will be recognized under the AbbVie domestic license agreement. Revenue under this agreement had previously been recognized under license and other revenue. The adoption of ASC 606 had no impact on the Company’s cash flows from operations. The aforementioned adjustments resulted in offsetting shifts in cash flows to net loss and change in deferred revenue. Transaction Price Allocated to Future Performance Obligations ASC 606 requires that the Company disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of September 30, 2018 . The guidance provides certain practical expedients that limit this requirement. The Company has various contracts that meet the following practical expedients provided by ASC 606: 1. The performance obligation is part of a contract that has an original expected duration of one year or less. 2. Revenue is recognized from the satisfaction of the performance obligations in the amount billable to the customer. 3. The variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation. The Company does not have any performance obligations, outside of the practical expedients above, that have not yet been satisfied as of September 30, 2018 and therefore there is no transaction price allocated to future performance obligations under ASC 606. Recent Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-15, “ I ntangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force)” , which requires customers in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in Accounting Standards Codification 350-40 to determine which implementation costs to capitalize as assets. This ASU is effective for annual or any interim periods beginning after December 15, 2019. The Company does not expect the standard to have a significant impact on its consolidated financial statements, as the Company’s cloud computing contracts are not material. In June 2018, the FASB issued ASU No. 2018-07, “ Compensation – Stock Compensation” , which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, except for specific exceptions. This ASU is effective for annual or any interim periods beginning after December 15, 2018. The Company does not expect the standard to have a significant impact on its consolidated financial statements, as the fair value of the Company’s awards to nonemployees is immaterial . In May 2017, the FASB issued ASU No. 2017-09, “ Compensation – Stock Compensation” , which clarifies the guidance about which changes to the terms and conditions of a share-based payments award require an entity to apply modification accounting in Topic 718. This ASU is effective for annual or any interim periods beginning after December 15, 2017. The Company adopted this standard on January 1, 2018, which did not impact the consolidated finan cial statements as the Company has not modified the terms and conditions of any share-based payments during the year ended December 31, 2017 or the nine months ended September 30, 2018 . In January 2017, the FASB issued ASU No. 2017-04, “ Intangibles – Goodwill and Other” , which simplifies the subsequent measurement of goodwill by eliminating “Step 2” from the goodwill impairment test. Instead of performing Step 2 to determine the amount of an impairment charge, the fair value of a reporting unit will be compared with its carrying amount and an impairment charge will be recognized for the value by which the carrying amount exceeds the reporting unit’s fair value. ASU 2017-04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not expect the standard to have a significant impact on its consolidated financial statements . In November 2016, the FASB issued ASU No. 2016-18, “ Statement of Cash Flows (Topic 230): Restricted Cash ”. This ASU requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total amounts on the balance sheet and disclose the nature of the restrictions. The Company adopted this standard on January 1, 2018, which did not have a significant impact on its consolidated financial statements as the Company’s restricted cash balances are immaterial. In February 2016, the FASB issued ASU No. 2016 ‑02, “ Leases ”. This ASU amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets. Current GAAP does not require lessees to recognize assets and liabilities arising from operating leases on the balance sheet. This guidance is effective for annual and interim reporting periods of public entities beginning after December 15, 2018, with early adoption permitted. In July 2018, the FASB issued ASU No. 2018-10, “Codification Improvements to Topic 842, Leases” and ASU 2018-11, “Leases (Topic 842): Targeted Improvements” . These ASU’s make improvements and provide clarity to several aspects of the guidance in ASC 842. The Company is in the process of implementation and expects to adopt this guidance when it becomes effective using the optional transition method allowed under the standard which does not require comparative periods to be restated. The Company expects to elect to apply practical expedients allowed under the standard, which, among other things, allows the carryforward of historical lease classifications. The Company expects that adoption of this standard will have a material impact on the Company’s consolidated balance sheets and related disclosures, as a result of recognizing a cumulative-effect adjustment reflecting right-of-use assets and lease liabilities related to its operating leases on January 1, 2019 . The Company does not expect a material impact to the consolidated statement of operations or cash flows. Prior period financial statements and related disclosures will be presented in accordance with ASC 840.

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2018
Stockholders’ Equity [Abstract]
Stockholders’ Equity	3. Stockholders’ Equity 5% Convertible Preferred Stock The Company had 30,000 shares of 5% convertible preferred stock outstanding at September 30, 2018 , which converts into shares of the Company’s common stock at a 20% discount to the price per share of common stock in the Company’s initial public offering (“IPO”) of $12.00 per share. T he Company accrued dividends on the 5% convertible preferred stock of $0.4 million and $1.2 million for the three and nine months ended September 30, 2018 , respectively and $0.3 million and $1.1 million for the three and nine months ended September 30, 2017 , respectively. T he Company calculated a deemed dividend of $0.1 million on the $0.4 million and $0.3 million of accrued dividends during each of the three months ended September 30, 2018 and 2017 , respectively, and $0.3 million on the $1.2 million and $1.1 million of accrued dividends during each of the nine months ended September 30, 2018 and 2017 , respectively, which is a beneficial conversion feature. Approximately $1.6 million and $1.4 million of accrued dividends that were payable on June 30, 2018 and June 30, 2017, respectively, were added to the stated liquidation preference amount of the 5% convertible preferred stock on those respective dates. The stated liquidation preference amount on the 5% convertible preferred stock totaled $33.0 million at September 30, 2018 .  Common Stock The Company’s certificate of incorporation authorizes the issuance of up to 200,000,000 shares of the Company’s common stock, par value $0.001 per share.

Net Loss per Share Attributable

Net Loss per Share Attributable to Common Stockholders	9 Months Ended
	Sep. 30, 2018
Net Loss per Share Attributable to Common Stockholders [Abstract]
Net Loss per Share Attributable to Common Stockholders	4. Net Loss per Share Attributable to Common Stockholders Basic net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Shares issued during the period are weighted for the portion of the period that they were outstanding. Because the Company has reported a net loss for the three and nine months ended September 30, 2018 and 2017 , diluted net loss per common share is the same as basic net loss per common share for those periods. The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except share and per share amounts):    Three Months Ended Nine Months Ended  September 30, September 30,  2018 2017 2018 2017  Numerator – basic and diluted:  Net loss available to common stockholders $ (14,314) $ (22,193) $ (14,231) $ (63,012)  Denominator – basic and diluted:  Weighted average common shares outstanding used to compute basic and diluted net loss per share 113,101,776 52,572,880 92,378,205 50,331,163  Net loss per share, basic and diluted $ (0.13) $ (0.42) $ (0.15) $ (1.25) The amounts in the table below were excluded from the calculation of diluted net loss per share, due to their anti-dilutive effect:     Three Months Ended Nine Months Ended  September 30, September 30,  2018 2017 2018 2017  Options to purchase common stock 9,713,427 3,310,843 9,713,427 3,310,843  Warrants to purchase common stock 11,999,852 6,067,447 11,999,852 6,067,447  Convertible preferred stock 3,476,385 12,945,590 3,476,385 12,945,590  Total shares of common stock equivalents 25,189,664 22,323,880 25,189,664 22,323,880 

Debt

Debt	9 Months Ended
	Sep. 30, 2018
Debt [Abstract]
Debt	5. Debt The Company is a party to one credit agreement in the following amount (in thousands):     September 30, December 31,  2018 2017   Secured term debt due July 1, 2020 $ 28,046 $ 34,620   Total debt before fees, interest and debt discount/premium 28,046 34,620  Less: Deferred financing costs — (228)  Debt discount (660) (1,030)  Add: Debt premium — 345  Total debt payable $ 27,386 $ 33,707   Debt payable, current portion $ — $ 33,707  Debt payable, long-term $ 27,386 $ —  Secured Term Debt August 2015 Secured Term Debt In August 2015, the Company entered into a secured term loan in the amount of $35.0 million with two lenders (“2015 Credit Agreement”). The interest rate on the loan is LIBOR plus 9.375% with a 1% floor. The Company incurred and paid a $0.8 million commitment fee in connection with the loan that will be amortized to interest expense over the term of the agreement. The basic terms of the loan required monthly payments of interest only, through the first anniversary date of the loan, and required the Company to maintain certain financial covenants requiring the Company to maintain a minimum liquidity amount and minimum revenue levels beginning after June 30, 2016 through August 1, 2016, the date the Company consummated its IPO. Beginning on the first anniversary date of the loan, the Company was required to make monthly principal payments in the amount of $380,000 . Any outstanding balance of the loan and accrued interest was to be repaid on June 17, 2018 . The secured term loan is collateralized by a first priority perfected security interest in all the tangible and intangible property of the Company. In conjunction with the 2015 Credit Agreement, warrants to purchase $6.3 million of Class A units were issued to two lenders, of which $5.4 million was recorded as a debt discount and $0.9 million was recorded as loss on extinguishment of debt (Note 6). The debt discount was amortized over the life of the outstanding term loan using the effective interest method. Deferred financing costs of $1.3 million were recognized in recording the 2015 Credit Agreement and were amortized to interest expense over the three year term of the agreement. There were no unamortized deferred financing costs at September 30, 2018 and approximately $0.2 million of unamortized deferred financing costs at December 31, 2017 . Approximately $0.2 million was charged to interest expense during the nine months ended September 30, 2018 and approximately $0.1 million and $0.4 million was charged to interest expense during the three and nine months ended September 30, 2017 . There was no expense recorded during the three months ended September 30, 2018 as the deferred financing costs were fully amortized as of June 30, 2018. The Company entered into a third waiver agreement to the 2015 Credit Agreement in September 2016 to negotiate the amendment and restatement of certain covenants of the Company contained in the 2015 Credit Agreement. In connection with such negotiation, the lenders under the 2015 Credit Agreement had agreed to refrain from exercising certain rights under the 2015 Credit Agreement, including the declaration of a default and to forbear from acceleration of any repayment rights with respect to existing covenants until the parties have consummated the amendment and restatement of such provisions. In addition, certain payments required to be made under the 2015 Credit Agreement had been deferred while the parties negotiated the amendment. The parties executed the Second Amendment to the 2015 Credit Agreement in November 2016 whereby the Company deferred further principal payments owed under the 2015 Credit Agreement in the amount of $380,000 per month until August 31, 2017. Additionally, the parties amended various clinical development milestones and added a covenant pursuant to which the Company was required to raise $40.0 million of additional equity capital by the end of the second quarter of 2017. All other material terms of the 2015 Credit Agreement, including the maturity date, remained the same. The Company entered into a fourth waiver agreement to the 2015 Credit Agreement in March 2017 under which the lenders under the 2015 Credit Agreement agreed to refrain from exercising certain rights under the 2015 Credit Agreement, including the declaration of a default and to forbear from acceleration of any repayment rights with respect to existing covenants. On March 31, 2017, the Company entered into the Third Amendment. Pursuant to this amendment, principal payments owed under the 2015 Credit Agreement, in the amount of $380,000 per month, were deferred until January 31, 2018. Additionally, the parties amended a future capital raising covenant by extending the time period by which the Company was required to raise the remaining $17.0 million of capital by six months, from June 30, 2017 to December 31, 2017, which was satisfied in September 2017. All other material terms of the 2015 Credit Agreement, including the maturity date, remained the same. The clinical development milestone was deemed satisfied in a letter agreement entered into on December 22, 2017 with a majority of lenders under our 2015 Credit Agreement. The Third Amendment also amended certain terms of the warrants to purchase an aggregate of 617,651 shares of the Company’s common stock issued in connection with the 2015 Credit Agreement (the “2015 Warrants”). Pursuant to the Third Amendment, the warrants may now only be exercised for cash and the exercise price was reduced from $10.20 per share to $4.50 per share. The redemption feature in the 2015 Warrants was also amended such that the warrant holder may only demand a redemption of the 2015 Warrants upon the occurrence of, and during the continuance of, an event of default. Prior to this amendment, the warrant could be redeemed by the warrant holder at any time after the 51 st month. As a result of the Third Amendment, $0.9 million was recorded as a debt premium at March 31, 2017, inclusive of the fair value of the warrant modification utilizing a Black-Scholes calculation, and will be amortized to interest expense over the remaining term of the agreement as the amendment was deemed to be a modification in accordance with ASC 470 (Note 6). Approximately $0.3 million was recorded to interest expense during the nine months ended September 30, 2018 , and a pproximately $0.2 million and $0.4 million was recorded to interest expense during the three and nine months ended September 30, 2017 , respectively. There was no expense recorded during the three months ended September 30, 2018 as the premium was fully amortized as of June 30, 2018 The Company entered into a fifth waiver agreement to the 2015 Credit Agreement in March 2018 under which the lenders under the 2015 Credit Agreement agreed to refrain from exercising certain rights under the 2015 Credit Agreement, including the declaration of a default and to forbear from acceleration of any repayment rights with respect to existing covenants. The report and opinion of the Company’s independent registered public accounting firm, BDO USA, LLP, for the year end December 31, 2017 contained an explanatory paragraph regarding the Company’s ability to continue as a going concern, which was an event of default under the 2015 Credit Agreement. The Company entered into the fourth amendment to the 2015 Credit Agreement in June 2018 (the “Fourth Amendment”). Pursuant to the Fourth Amendment, the maturity date of the 2015 Credit Agreement was extended to August 31, 2018 (the “Extension Period”). The Company repaid $4.7 million of the outstanding principal on June 18, 2018, representing all amounts due under the 2015 Credit Agreement to GoldenTree Credit Opportunities, LP, GoldenTree Credit Opportunities, Ltd, GoldenTree Insurance Fund Series Interests of the SALI Multi-Series Fund, LP, GT NM, LP, and San Berndino County Employees’ Retirement Association. All other material terms of the 2015 Credit Agreement remained the same during the Extension Period. The Company entered into the fifth amendment to the 2015 Credit Agreement in August 2018 (the “Fifth Amendment”). Pursuant to the Fifth Amendment, the maturity date of the Credit Agreement was extended to July 1, 2020 and principal payments have been deferred until January 31, 2020. Beginning on January 31, 2020, equal principal payments of $750,000 per month will be due until the maturity date. Additionally, the parties amended certain covenants under the 2015 Credit Agreement to require the Company to meet certain developmental milestones by December 31, 2019. All other material terms of the 2015 Credit Agreement remain the same, including a minimum liquidity covenant. As of the date hereof, the Company is not in default under the terms of the 2015 Credit Agreement. The Fifth Amendment also amended the exercise price of a portion of the 2015 Warrants to purchase an aggregate of 529,413 shares of the Company’s common stock from $4.50 per warrant share to $3.30 per warrant share. The terms of the remaining 2015 Warrants to purchase an aggregate of 88,238 shares of the Company’s common stock remain the same. As amended, if all of the 2015 Warrants are exercised, the Company will receive approximately $2.1 million in cash proceeds. As a result of the Fifth Amendment, $0.7 million was recorded as a debt discount in August 2018, inclusive of the fair value of the warrant modification utilizing a Black-Scholes calculation, and will be amortized to interest expense over the remaining term of the agreement as the amendment was deemed to be a modification in accordance with ASC 470 (Note 6). Approximately $0.1 million was recorded to interest expense during each of the three and nine months ended September 30, 2018 . The minimum payments required on the outstanding balances of the 2015 Credit Agreement at September 30, 2018 for each of the years ended December 31 are (in thousands):    2015 Credit Agreement  2018 $ —  2019 —  2020 28,046  $ 28,046  The following table provides components of interest expense and other related financing costs (in thousands):     Three Months Ended Nine Months Ended  September 30, September 30,  2018 2017 2018 2017  Interest expense and other financing costs $ 830 $ 955 $ 2,720 $ 2,772  Amortization of deferred financing costs, debt discount and debt premium 47 514 960 1,727  Interest expense $ 877 $ 1,469 $ 3,680 $ 4,499 

Financial Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2018
Financial Instruments [Abstract]
Financial Instruments	6. Financial Instruments Equity issued pursuant to Credit Agreements In connection with the 2015 Credit Agreement, the Company issued warrants as fees to the lenders to purchase an aggregate of $6.3 million of the Company’s Class A units. The strike price of the warrants was 85% of the price per unit in an IPO or, if before an IPO, 85% of the deemed per unit equity value as defined in the 2015 Credit Agreement. The warrants were exercisable as of the earlier of an IPO or July 1, 2016. Since these warrants are also redeemable at the option of the holder upon the occurrence of, and during the continuance of, an event of default , the warrants are recorded as a liability of $1.2 million at both September 30, 2018 and December 31, 2017 . Upon entry into the agreement in August 2015, the warrants issued to an existing lender was recorded to loss on extinguishment of debt of $0.9 million and the warrants issued to the new lender was recorded as a debt discount of $5.4 million and will be amortized over the three year term (Note 5) in accordance with ASC 470. As a result of the Third Amendment, $0.9 million was recorded as a debt premium and will be amortized to interest expense over the remaining term of the agreement as the Third Amendment was deemed to be a modification in accordance with ASC 470. As a result of the Fifth Amendment, the fair value of the warrant modification calculated utilizing the Black-Scholes valuation model of $0.1 million was recorded as a debt discount in August 2018, and will be amortized to interest expense over the remaining term of the agreement as the amendment was deemed to be a modification in accordance with ASC 470 . The Company used the Black-Scholes pricing model to value the warrant liability at September 30, 2018 with the following assumptions: risk-free interest rate of 2.9% , expected term of 3.9 years, expected volatility of 82.9% and a dividend rate of 0% . Upon consummation of the Company’s IPO on August 1, 2016 with a price per share of common stock in the IPO of $12.00, the warrants to purchase Class A units issued to lenders under the 2015 Credit Agreement were exchanged for 617,651 warrants to purchase the same number of shares of the Company’s common stock. The change in fair value of the warrants was $(0.2) million and $(0.1) million for the three and nine months ended September 30, 2018 , respectively, and $(0.3) million and $(2.2) million for the three and nine months ended September 30, 2017 , respectively. None of these instruments have been exercised as of September 30, 2018 and December 31, 2017 . At September 30, 2018 , the fair value of the warrant liability was approximately $1.2 million and is recorded as a short-term liability as the 2015 Warrants are exercisable. Other Warrants In connection with the sale of common stock in March 2017, warrants to purchase 2,707,138 shares of common stock were issued at an exercise price of $4.50 per share. During April 2018, warrants to purchase 119,047 shares of common stock were exercised for which the Company received proceeds of $0.5 million. The remaining 2,588,091 warrants expired i n April 2018. These warrants included a cash settlement option requiring the Company to record a liability for the fair value of the warrants at the time of issuance and at each reporting period with any change in the fair value reported as other income or expense. At the time of issuance, approximately $1.6 million was recorded as a warrant liability. The change in the fair value of these warrants was $(0.7) million for the nine months ended September 30, 2018 , and $(1.1) million and $(0.8) million for the three and nine months ended September 30, 2017 , respectively. In connection with the 2017 Public Offering, the Company issued warrants to purchase 10,710,000 shares of common stock at an initial exercise price of $3.35 per share for a term of 5 years from the date of issuance. At September 30, 2018 , warrants to purchase 10,671,400 shares of common stock were outstanding. The Company assessed the warrants under FASB ASC 480 and determined that the warrants were outside the scope of ASC 480. The Company next assessed the warrants under FASB ASC 815. Under the related guidance, a reporting entity shall not consider a contract to be a derivative instrument if the contract is both (1) indexed to the entity’s own stock and (2) classified in stockholders’ equity. The Company determined that the warrants were indexed to the Company’s stock, as the agreements do not contain any exercise contingencies and the warrants’ settlement amount equals the difference between the fair value of the Company’s common stock price and the warrant strike price. The Company also assessed the classification in stockholders’ equity and determined the warrants met all of the criteria for classification as equity under ASC 815. Based on this analysis, the Company determined that the warrant should be classified as equity and recorded $22.8 million to additional paid in capital, which represents the allocation of the 2017 Public Offering proceeds to the fair value of the warrants at issuance date. Fair Value of Long ‑term Debt The Company maintained a long-term secured term debt balance of $28.0 million at September 30, 2018 . The Company had no long-term secured debt at December 31, 2017 . Since the secured debt becomes due on July 1, 2020 , it has been recorded as long-term secured debt at September 30, 2018 . The underlying agreements for these balances were negotiated with parties that included fully independent third parties, at an interest rate which is considered to be in line with over-arching market conditions. Based on these factors management considers the carrying value of the debt to approximate fair value at September 30, 2018 and December 31, 2017 . Fair Value Classification The Company held certain liabilities that are required to be measured at fair value on a recurring basis. Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: · Level 1—Quoted prices in active markets for identical assets or liabilities. · Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. · Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.  The table below represents the values of the Company’s financial instruments at September 30, 2018 and December 31, 2017 (in thousands):    Fair Value Measurement Using Significant Other Observable Inputs (Level 2)   September 30, December 31,  Description 2018 2017  Warrants $ 1,247 $ 1,952  Total $ 1,247 $ 1,952  The table below represents a rollforward of the Level 2 financial instruments from January 1, 2017 to September 30, 2018 (in thousands).    Significant Other Observable Inputs  (Level 2)  Balance at January 1, 2017 $ 3,305  Fair value of warrants modified in the Third Amendment (908)  Issuance of warrants in private placement 1,651  Change in fair value of financial instruments (2,096)  Balance at December 31, 2017 $ 1,952  Change in fair value of financial instruments (802)  Fair value of warrants modified in the Fifth Amendment 111  Exercise of warrants recorded as liability (14)  Balance at September 30, 2018 $ 1,247  The Level 2 inputs used to value our financial instruments were determined using prices that can be directly observed or corroborated in active markets. Although the fair value of this obligation is calculated using the observable market price of Kadmon Holdings Inc. common stock, an active market for this financial instrument does not exist and therefore the Company has classified the fair value of this liability as a Level 2 liability in the table above.  Warrants The following table summarizes information about warrants outstanding at September 30, 2018 and December 31, 2017 :     Warrants Weighted Average Exercise Price  Balance, December 31, 2017 14,722,790 $ 5.70  Granted — —  Exercised (134,847) 4.21  Forfeited (2,588,091) 4.50  Balance, September 30, 2018 11,999,852 $ 5.97 

Inventories

Inventories	9 Months Ended
	Sep. 30, 2018
Inventories [Abstract]
Inventories	7. Inventories Inventories are stated at the lower of cost or net realizable value (on a first ‑in, first ‑out basis) using standard costs. Standard costs include an allocation of overhead rates, which include those costs attributable to managing the supply chain and are evaluated regularly. Variances are expensed as incurred. The Company regularly reviews the expiration dates of its inventories and maintains a reserve for inventories that are probable to expire before shipment. Inventories recorded on the Company’s consolidated balance sheets are net of a reserve for expirable inventory of $3.5 million and $4.8 million at September 30, 2018 and December 31, 2017 , respectively. The Company expensed Ribasphere inventory that it believes will not be sold prior to reaching its expiration date totaling less than $ 0.1 million and $0.3 million during the three and nine months ended September 30, 2018 , respectively, and $0.9 million and $1.7 million during the three and nine months ended September 30, 2017 , respectively. If the amount and timing of future sales differ from management’s assumptions, adjustments to the estimated inventory reserves may be required. Inventories Produced in Preparation for Product Launches  The Company capitalizes inventories produced in preparation for product launches sufficient to support estimated initial market demand. Typically, capitalization of such inventory begins when positive results have been obtained for the clinical trials that the Company believes are necessary to support regulatory approval, uncertainties regarding ultimate regulatory approval have been significantly reduced and the Company has determined it is probable that these capitalized costs will provide some future economic benefit in excess of capitalized costs. The material factors considered by the Company in evaluating these uncertainties include the receipt and analysis of positive Phase 3 clinical trial results for the underlying product candidate, results from meetings with the relevant regulatory authorities prior to the filing of regulatory applications, and the compilation of the regulatory application. The Company closely monitors the status of each respective product within the regulatory approval process, including all relevant communication with regulatory authorities. If the Company is aware of any specific material risks or contingencies other than the normal regulatory review and approval process or if there are any specific issues identified relating to safety, efficacy, manufacturing, marketing or labeling, the related inventory would generally not be capitalized. For inventories that are capitalized in preparation of product launch, anticipated future sales, expected approval date and shelf lives are evaluated in assessing realizability. The shelf life of a product is determined as part of the regulatory approval process; however in evaluating whether to capitalize pre-launch inventory production costs, the Company considers the product stability data of all of the pre-approval production to date to determine whether there is adequate expected shelf life for the capitalized pre-launch production costs. The Company has concluded that KD034, its generic version of trientine hydrochloride, is commercially viable since it is the chemical equivalent of the original drug approved by the U.S. Food and Drug Administration (“FDA”). The Company has submitted two Abrreviated New Drug Application’s with the FDA, and economic benefits are probable. Accordingly, the pre-launch costs are realizable as the Company expects the inventory will be sold or used prior to expiration. An assessment of likelihood that regulatory approval will not be obtained will be made at each reporting period. If at any time regulatory approval is deemed to not be probable, the inventory will be written down to its net realizable value, which is presumably zero, as the product would have no alternative future use. The Company maintained $1.0 million and $0.1 million of work-in-process inventory related to KD034 at September 30, 2018 and December 31, 2017 , respectively. Inventories are comprised of the following (in thousands):        September 30, December 31,  2018 2017  Work-in-process 1,032 80  Finished goods, net 31 121  Total inventories $ 1,063 $ 201  

Fixed Assets

Fixed Assets	9 Months Ended
	Sep. 30, 2018
Fixed Assets [Abstract]
Fixed Assets	8. Fixed Assets Fixed assets consisted of the following (in thousands):     Useful Lives September 30, December 31,  (Years) 2018 2017   Leasehold improvements 4 -8 $ 10,187 $ 10,120  Office equipment and furniture 3 -15 1,529 1,488  Machinery and laboratory equipment 3 -15 3,242 2,765  Software 1 -5 3,624 3,162  Construction-in-progress ̶̶̶̶ 201 408  18,783 17,943  Less accumulated depreciation and amortization (14,756) (13,651)  Fixed assets, net $ 4,027 $ 4,292  Depreciation and amortization of fixed assets totaled $1.1 million and $1.4 million during the nine months ended September 30, 2018 and 2017 , respectively, and $0.4 million and $0.5 million in the three months ended September 30, 2018 and 2017 , respectively. The construction ‑in ‑progress balance is related to costs of unimplemented software still under development. Unamortized computer software costs were $0.6 million and $0.2 million at September 30, 2018 and December 31, 2017 , respectively. The amortization of computer software costs amounted to $0.1 million and $0.5 million for the nine months ended September 30, 2018 and 2017 , respectively , and $0.2 million for the three months ended September 30, 2017 . No meaningful amortization of computer software costs was recorded for the three months ended September 30, 2018 . During the first quarter of 2017, the Company disposed of $2.1 million of fully depreciated assets. There was no consideration received for the disposal of these assets and the disposal did not have a significant impact on the consolidated financial statements of the Company .

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2018
Goodwill [Abstract]
Goodwill	9. Goodwill The Company’s goodwill relates to the 2010 acquisition of Kadmon Pharmaceuticals, LLC, a Pennsylvania limited liability company that was formed in April 2000. There were no changes in the carrying amount of goodwill for the nine months ended September 30, 2018 and the year ended December 31, 2017 .

Investment in MeiraGTx

Investment in MeiraGTx	9 Months Ended
	Sep. 30, 2018
Investment in MeiraGTx [Abstract]
Investment in MeiraGTx	10. Investment in MeiraGTx In April 2015, the Company executed several agreements which transferred its ownership of Kadmon Gene Therapy, LLC to MeiraGTx. As part of these agreements, the Company also transferred various property rights, employees and management tied to the intellectual property and contracts identified in the agreements to MeiraGTx. At a later date, MeiraGTx ratified its shareholder agreement and accepted the pending equity subscription agreements, which provided equity ownership to various parties. The execution of these agreements resulted in a 48% ownership in MeiraGTx by the Company. After MeiraGTx was deconsolidated or derecognized, the retained ownership interest was initially recognized at fair value and a gain of $24.0 million was recorded based on the fair value of this equity investment. The Company’s investment was accounted for under the equity method at zero cost with an estimated fair value at the time of the transaction of $24.0 million. This value was determined based upon the implied value established by the cash raised by MeiraGTx in exchange for equity interests by third parties. As of March 31, 2018, the Company had no basis in any of the investments in MeiraGTx. The Company assessed the applicability of ASC 810 to the aforementioned agreements and based on the corporate structure, voting rights and contributions of the various parties in connection with these agreements, determined that MeiraGTx is a variable interest entity, however consolidation is not required as the Company is not the primary beneficiary based upon the voting and managerial structure of the entity. On June 12, 2018, MeiraGTx completed its initial public offering (the “MeiraGTx IPO”) whereby it sold 5,000,000 shares of common stock at $15.00 per share. Upon the closing of the MeiraGTx IPO, 27,184,132 shares of common stock were outstanding, which includes the conversion of all C preferred shares into common stock. The shares began trading on the Nasdaq Global Select Market on June 7, 2018 under the symbol “MGTX.” Prior to the MeiraGTx IPO, the Company had no basis in any of the investments held in MeiraGTx. Upon completion of the MeiraGTx IPO, the Company’s investment was diluted to 13.0% ownership in MeiraGTx common stock and no longer has the ability to exert significant influence over MeiraGTx. The Company discontinued the equity method of accounting for the investment in MeiraGTx on June 12, 2018 and determined the remaining investment to be an equity security accounted for in accordance with ASC 321 at the date the investment no longer qualifies for the equity method of accounting. ASC 321 requires the investments to be recorded at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. As the Company’s investment in MeiraGTx common stock has a readily determinable market value, the Company recorded an unrealized gain of $40.5 million in June 2018 related to the fair value of its ownership of common stock of MeiraGTx. As of September 30, 2018 , the Company maintains a 13.0% ownership in the common stock of MeiraGTx with a fair value of $48.1 million recorded as a noncurrent investment in equity securities as the Company is restricted from trading during the 180 day lock-up period from the date of the MeiraGTx IPO. The Company has recorded an unrealized gain on the MeiraGTx common stock investment of $7.6 million and $48.1 million for the three and nine months ended September 30, 2018 , respectively. The investment in MeiraGTx is valued using Level 1 inputs which includes quoted prices in active markets for identicial assets in accordance with the fair value hierarchy (see Note 6). The Company has not realized any gains related to the investment in common stock of MeiraGTx. As part of the agreements executed with MeiraGTx in April 2015, the Company entered into a transition services agreement (“TSA”) with MeiraGTx which expired in April 2018. Upon expiration of the TSA, the Company continued to provide office space to MeiraGTx. On October 1, 2018 , the Company and MeiraGTx entered into a sublease agreement which is effective from October 1, 2018 for a period of two months and will automatically be renewed on a monthly basis unless MeiraGTx provides 30 days prior written notice . The mo nthly sublease amount is approximately $47,000 . As part of the TSA and sublease agreement with MeiraGTx, the Company recognized $0.4 million to license and other revenue during each of the nine months ended September 30, 2018 and 2017 and $0.1 million during each of the three months ended September 30, 2018 and 2017 . The Company received cash payments of $1.3 million and $0.3 million from MeiraGTx during the nine months ended September 30, 2018 and 2017 , respectively. The Company has immaterial amounts receivable from MeiraGTx at September 30, 2018 and $0.9 million of amounts receivable from MeiraGTx at December 31, 2017 . For the period beginning January 1, 2018 through June 12, 2018, the Company recorded its share of MeiraGTx’s net loss under the equity method of accounting of $1.2 million. For the the three and nine months ended September 30, 2017 the Company recorded its share of MeiraGTx’s net loss under the equity method of accounting of $1.8 million and $7.5 million, respectively. In February 2016, MeiraGTx entered into a five -year lease with Moorfields Eye Hospital and NHS Foundation Trust. Under the lease, Kadmon is a guarantor of MeiraGTx’s rent obligations and has agreed to indemnify Moorfields as the landlord against any failure by MeiraGTx to pay the rent or otherwise perform its obligations thereunder. Remaining payments under the lease are approximately $0.7 million.

License Agreements

License Agreements	9 Months Ended
	Sep. 30, 2018
License Agreements [Abstract]
License Agreements	11. License Agreements The Company’s license agreements are disclosed in the audited financial statements included in Item 8 of the Annual Report on Form 10-K as of and for the year ended December 31, 2017 . Since the date of such financial statements, there have been no changes to the Company’s license agreements, other than those described below. Dyax Corp. (acquired by Shire Plc in January 2016) On September 13, 2012 the Company entered into a license agreement with Dyax whereby the Company obtained from Dyax the exclusive, worldwide license to use research, develop, manufacture and commercialize DX ‑2400 in exchange for payment of $0.5 million. All payments associated with this agreement were recorded as research and development expense at the time the agreement was executed. On April 2, 2018, we gave notice of our intent to terminate this agreement effective six months from the date of notice. Oncon and Ras On May 19, 2016, the Company entered into a development and license agreement with Limited Liability Company Oncon (“Oncon”) whereby the Company granted Oncon exclusive licenses for certain antibodies. While Oncon is not considered a related party to Kadmon, a family member of a former executive of Kadmon is a limited, non-controlling partner and minority shareholder in Oncon who is unable to exert significant influence on the policies or operations of Oncon. Upon commercial sale of the licensed antibodies, the Company is eligible to receive a royalty equal to a percentage of net sales in the high-teens. The Company is also eligible to receive a portion of sublicensing revenue from Oncon ranging from the low ten percents to low thirty percents based on the development stage of the product. No such revenue was earned during the three and nine months ended September 30, 2018 and 2017 . In connection with the development and license agreement, the Company also entered into an exclusive supply agreement with Limited Liability Company Ras (“Ras”) whereby the Company will supply Ras with antibodies under the agreement for Ras to supply to Oncon. Ras is controlled by the family member of a former executive of Kadmon and was a related party to Kadmon until the resignation of the executive on October 24, 2018, at which point Ras ceased to be a related party. There has been no activity between the Company and Ras under the development and license agreement as of September 30, 2018 .  On April 20, 2018, the Company entered into a cell bank development and royalty agreement with Oncon whereby the Company would serve as an agent to engage a third party to develop and manufacture a biological product for Oncon. Under the cell bank development agreement, Ras is Oncon’s designated recipient of the master cell bank, if and when its development is complete. There has been no activity between the Company and Ras under the cell bank development agreement as of September 30, 2018 . In June 2018, the Company received an upfront payment from Oncon totaling $0.8 million which the Company is required to deliver to the third party upon completion of development of the master cell bank. At September 30, 2018 , the Company has $0.8 million recorded as an accrued liability as no payments have been made to the third party as of September 30, 2018 . Under this agreement, the Company is also to provide expertise and know-how to the development process and is eligible to receive a royalty equal to a percentage of net sales in the low single digit percents upon commercialization of the biological product. The Company is also eligible to receive a portion of sublicensing revenue from Oncon in the low single digit percents. No such revenue was earned during the three and nine months ended September 30, 2018 and 2017 .

Share-based Compensation

Share-based Compensation	9 Months Ended
	Sep. 30, 2018
Share-based Compensation [Abstract]
Share-based Compensation	12. Share ‑based Compensation 2016 Equity Incentive Plan A total of 8,523,147 shares of the Company’s common stock were authorized and reserved for issuance under the Company’s 2016 Equity Incentive Plan, as amended (the “2016 Equity Plan”) at December 31, 2017. This reserve automatically increased to 11,668,905 on January 1, 2018 and will automatically increase each subsequent anniversary through January 1, 2025, by an amount equal to the smaller of (a) 4% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (b) an amount determined by the board of directors. At September 30, 2018 , there were options to purchase an aggregate of 8,115,927 shares of common stock outstanding at a weighted average price of $7.06 per share under the 2016 Equity Plan. Total unrecognized compensation expense related to unvested options granted under the Company’s share ‑based compensation plan was $6.2 million and $13.3 million at September 30, 2018 and December 31, 2017 , respectively. That expense is expected to be recognized over a weighted average period of 1.7 years and 1.9 years as of September 30, 2018 and December 31, 2017 , respectively. The Company recorded share ‑based compensation expense under the 2016 Equity Plan of $ 8.4 million and $10.6 million for the nine months ended September 30, 2018 and 2017 , respectively, and $2.8 million and $13.2 million for the three months ended September 30, 2018 and 2017 , respectively. The following table summarizes information about stock options outstanding at September 30, 2018 and December 31, 2017 :    Options Outstanding  Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands)  Balance, December 31, 2017 8,496,872 $ 6.96 8.83 $ —  Granted 280,924 4.62  Exercised — —  Forfeited (661,869) 4.78  Balance, September 30, 2018 8,115,927 $ 7.06 8.08 $ —  Options vested and exercisable, September 30, 2018 4,271,886 $ 9.69 7.37 $ —  The aggregate intrinsic value in the table above represents the total pre ‑tax intrinsic value calculated as the difference between the fair value of the Company’s common stock at September 30, 2018 ( $3.34 per share) and the exercise price, multiplied by the related in ‑the ‑money options that would have been received by the option holders had they exercised their options at the end of the fiscal year. This amount changes based on the fair value of the Company’s common stock. There were no options exercised during the nine months ended September 30, 2018 and 2017 . There were 280,924 stock options granted during the nine months ended September 30, 2018 with a weighted-average exercise price of $4.62 . During the nine months ended September 30, 2017 , 285,000 stock options were granted with a weighted ‑average exercise price of $4.11 . The fair value of each stock option award was estimated at the date of grant using the Black ‑Scholes option ‑pricing model and the assumptions noted in the following table:     Nine Months Ended Nine Months Ended  September 30, 2018 September 30, 2017  Weighted average fair value of grants $2.20 $2.62  Expected volatility 72.94% - 75.14% 74.48% -74.70%  Risk-free interest rate 2.44% - 2.84% 1.87% -2.00%  Expected life (years) 5.50 - 6.00 5.50 -5.75  Expected dividend yield 0% 0% Peformance Awards On April 3, 2018 the Company granted 1,597,500 nonqualified performance-based stock options (“Performance Options”) to certain executive officers (each, a “Grantee”), which represents the maximum number of Performance Options that may be earned if all three performance milestones (each, a “Performance Goal”) are achieved during the three -year period following the Grant Date (the “Performance Period”), as described below. If two of the three Performance Goals are achieved during the Performance Period, two -thirds of the Performance Options may be earned (the “Target” number of Performance Options), and if one of the three Performance Goals are achieved during the Performance Period (the minimum performance threshold for the Performance Options), one -third of the Performance Options is earned. In addition to the achievement of the Performance Goals, the Performance Options are also subject to time-based vesting requirements. Each Performance Option was granted with an exercise price of $4.06 per share and does not contain any voting rights. No Performance Options were granted under the 2016 Equity Plan prior to 2018.  The Performance Options may be earned based on the achievement of three separate Performance Goals related to the Company’s operating and research and development activities during the Performance Period, subject to the Grantee’s employment through the achievement date. If no Performance Goals are achieved during the Performance Period, the Performance Options will be forfeited. Any Performance Options earned upon the achievement of a Performance Goal will generally vest in three equal installments on specified vesting dates between the date of achievement of the Performance Goal and the third anniversary of the Grant Date based on continued employment; provided , that, if the relevant achievement date for a Performance Goal occurs after the second anniversary of the Grant Date, the full vesting of the Options earned will occur on the one year anniversary of the date of achievement of the applicable Performance Goal. Unvested Performance Options will be forfeited upon the Grantee’s termination of employment, unless the Grantee is terminated without cause or resigns for good reason or due to the Grantee’s death or disability, in which case earned but unvested Performance Options will accelerate and vest (and unearned Performance Options will be forfeited). If the Grantee is terminated for cause, all Performance Options, whether earned, unearned, vested or unvested, will be forfeited. If a change in control (as defined in the 2016 Equity Plan) occurs during the Performance Period, the Target number of Performance Options will be deemed earned (if not previously earned), and any unearned Performance Options will be forfeited. In addition, following a change in control (whether such change in control occurs within or after three years following the Grant Date), and subject to the terms of the 2016 Equity Plan, Performance Options earned upon such change in control will vest on the first anniversary of the change in control based on continued employment, and any Performance Options earned prior to the change in control will vest no later than the first anniversary of the change in control based on continued employment; provided , that, in each case, any unvested Performance Options will vest upon a Grantee’s earlier termination by the Company without cause or resignation for good reason.  The weighted-average fair value of the Performance Options granted was $2.71 and was estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions: risk-free interest rate of 2.67% , expected term of 6.0 years, expected volatility of 74.50% , and a dividend rate of 0% . Compensation expense for the Performance Options is recognized on a straight-line basis over the awards’ requisite service period. The Performance Options vest upon the satisfaction of both a service condition and the satisfaction of one or more performance conditions, therefore the Company initially determined which outcomes are probable of achievement. The Company believes that the three-year service condition (explicit service period) and all three performance conditions (implicit service periods) will be satisfied. The requisite service period would be three years as that is the longest period of both the explicit service period and the implicit service periods. Total unrecognized compensation expense related to unvested Performance Options was $2.9 million at September 30, 2018 . The unrecognized compensation cost is expected to be recognized over a weighted-average period of 1.6 years. The weighted average remaining contractual term of the Performance Options is 9.5 years. No Performance Options were exercised during the nine months ended September 30, 2018 . Stock Appreciation Rights The Company granted 1,040,000 stock appreciation rights to certain executive officers during the year ended December 31, 2017 with an exercise price of $3.64 per share. No stock appreciation rights were granted under the 2016 Equity Plan prior to 2017. The weighted average remaining contractual term of the stock appreciation rights is 9.2 years. Compensation expense for stock appreciation rights is recognized on a straight-line basis over the awards’ requisite service period. Total unrecognized compensation expense related to unvested stock appreciation rights was $1.8 million and $2.5 million at September 30, 2018 and December 31, 2017 , respectively. The unrecognized compensation cost is expected to be recognized over a weighted-average period of 2.2 years and 2.9 years, respectively. No stock appreciation rights were exercised during the nine months ended September 30, 2018 and 2017 . The stock appreciation rights had no aggregate intrinsic value as of September 30, 2018 . 2014 Long ‑term Incentive Plan (“LTIP”) A total of 9,750 units were granted under the LTIP at September 30, 2018 and December 31, 2017 . The LTIP is payable upon the fair market value of the Company’s common stock exceeding 333% of the $6.00 grant price ( $20.00 ) per share prior to December 7, 2024. The holders of the LTIP have no right to demand a particular form of payment, and the Company reserves the right to make payment in the form of cash or common stock. 2016 Employee Stock Purchase Plan (“2016 ESPP”) A total of 1,801,180 shares of the Company’s common stock were reserved for issuance under the 2016 ESPP at December 31, 2017 , which increased to 2,551,180 on January 1, 2018. The 2016 ESPP was amended and restated on March 16, 2018. The Company issued 10,594 shares, 22,958 shares and 29,041 shares of common stock under the 2016 ESPP in October 2017, April 2018 and October 2018, respectively. No meaningful compensation expense was recognized for the ESPP during the nine months ended September 30, 2018 and 2017 .

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2018
Accrued Expenses [Abstract]
Accrued Expenses	13. Accrued Expenses Short ‑term accrued expenses at September 30, 2018 and December 31, 2017 include the following (in thousands):     September 30, December 31,  2018 2017  Commission payable $ 2,395 $ 2,395  Compensation and benefits 408 758  Severance 569 1,122  Research and development 3,229 1,915  Other 2,913 2,387  Total Accrued Expenses $ 9,514 $ 8,577  Commission Payable During 2014 and 2015, the Company raised $40.4 million in gross proceeds, $37.3 million net of $3.1 million in transaction costs, through the issuance of 3,514,859 Class E redeemable convertible units. Of the $3.1 million in transaction costs, $2.4 million remains in accrued liabilities at September 30, 2018 and December 31, 2017 relating to commissions to third parties for Class E redeemable convertible raises during 2014 and 2015. Severance Severance balances represent contractual compensation to be paid to former employees, a significant portion of which relates to the separation agreement with Dr. Samuel D. Waksal. Effective as of February 8, 2016, Dr. Samuel D. Waksal resigned from all positions with the Company and is no longer employed by the Company in any capacity. At September 30, 2018 , accrued severance payments payable to Dr. Samuel D. Waksal total $0.4 million, which is recorded as accrued expense. At December 31, 2017, accrued severance payable to Dr. Samuel D. Waksal totaled $1.2 million, of which $1.0 million was recorded as accrued expense and $0.2 million was recorded as other long ‑ term liabilities. The separation agreement with Dr. Samuel D. Waksal contains certain supplement conditional payments, none of which have been met at September 30, 2018 . The Company has not recorded any expense related to these conditional payments at September 30, 2018 and will continue to evaluate the probability of these conditional payments. Research and Development The Company has contracts with third parties for the development of the Company’s product candidates. The timing of the expenses varies depending upon the timing of initiation of clinical trials and enrollment of patients in clinical trials. At September 30, 2018 and December 31, 2017 , accrued research and development expenses for which the Company has not yet been invoiced totaled $3.2 million and $1.9 million, respectively.

Commitments

Commitments	9 Months Ended
	Sep. 30, 2018
Commitments [Abstract]
Commitments	14. Commitments The Company’s commitments are disclosed in the audited financial statements included in Item 8 of the Annual Report on Form 10-K as of and for the year ended December 31, 2017 . Since the date of such financial statements, there have been no changes to the Company’s commitments. Licensing Commitments The Company has entered into several license agreements for products currently under development (Note 11). The Company may be obligated in future periods to make additional payments, which would become due and payable only upon the achievement of certain research and development, regulatory, and approval milestones. The specific timing of such milestones cannot be predicted and depends upon future discretionary clinical developments as well as regulatory agency actions which cannot be predicted with certainty (including action which may never occur). These additional contingent milestone payments aggregate to $215.9 million at September 30, 2018 . Any payments made prior to FDA approval will be expensed as research and development. Payments made after FDA approval will be capitalized.  Further, under the terms of certain licensing agreements, the Company may be obligated to pay commercial milestones contingent upon the realization of sales revenues and sublicense revenues. Due to the long ‑range nature of such commercial milestones, they are neither probable at this time nor predictable, and consequently are not included in the additional contingent milestone payment amount. 

Contingencies

Contingencies	9 Months Ended
	Sep. 30, 2018
Contingencies [Abstract]
Contingencies	15. Contingencies The Company has been subject to various legal proceedings that arise from time to time in the ordinary course of its business. Although the Company believes that the various proceedings brought against it have been without merit, and that it has adequate product liability and other insurance to cover any claims, litigation is subject to many factors which are difficult to predict and there can be no assurance that the Company will not incur material costs in the resolution of legal matters. Should the Company determine that any future obligations will exist, the Company will record expense equal to the amount which is deemed probable and estimable. Legal Proceedings The Glodek Litigation On July 25, 2016, Kevin Glodek filed and served a Summons with Notice against Kadmon Holdings, LLC and Kadmon Holdings, Inc. in the New York State Supreme Court, for the county of New York, for an amount of no less than $2.8 million with interest, plus costs and disbursements. Company counsel demanded a complaint and that complaint was served and filed on September 6, 2016. In the complaint, Glodek alleges fraud, misrepresentation, breach of contract, breach of the implied covenant of good faith and fair dealing, and unjust enrichment, for amounts to be determined at trial, but in no event less than $4 million with interest, plus costs and disbursements. Glodek’s claims arise out of a 2015 settlement agreement, in which he released all claims he had against Kadmon Holdings, LLC and Kadmon Holdings, Inc. On September 21, 2016, Glodek filed an Amended Summons and an Amended Complaint adding Mr. Steven N. Gordon and a former executive of the Company as named defendants. All defendants moved (i) to dismiss the Amended Complaint and (ii) for sanctions or, in the alternative, to disqualify Glodek’s counsel. Argument on the motions was conducted on January 24, 2017 before the Honorable Anil Singh. On April 18, 2017, the complaint was dismissed in its entirety. Having previously noticed an appeal from that dismissal, Glodek filed his opening appellate brief on July 10, 2018. The defendants filed their brief, which included a cross-appeal seeking sanctions and argument was heard before the Appellate Division on October 26, 2018 and the Company is awaiting the decision.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	16. Related Party Transactions At December 31, 2016 Kadmon I, LLC held approximately 12.1% of the total outstanding common stock of Kadmon Holdings. The sole manager of Kadmon I, LLC was an executive officer of the Company. Kadmon I had no special rights or preferences in connection with its investment into Kadmon Holdings, and had the same rights as all other holders of Kadmon Holdings Class A units. On January 23, 2017, Kadmon I, LLC was dissolved and liquidated. Upon dissolution and liquidation, all assets of Kadmon I, LLC which consists solely of the shares of common stock in Kadmon Holdings, Inc., were distributed to the members of Kadmon I, LLC.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2018
Income Taxes [Abstract]
Income Taxes	17. Income Taxes The Company files a consolidated tax return for Kadmon Holdings, Inc. and its domestic subsidiaries and the required information returns for its international subsidiaries, all of which are wholly owned. Where permitted, the Company files combined state returns, but in some instances separate returns for certain subsidiaries on a stand ‑alone basis are required. Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s deferred tax assets relate primarily to its net operating loss carryforwards and other balance sheet basis differences. In accordance with ASC 740, “Income Taxes,” the Company recorded a valuation allowance to fully offset the gross deferred tax asset, because it is more likely than not that the Company will not realize future benefits associated with these deferred tax assets at September 30, 2018 and December 31, 2017 .  The Tax Cuts and Jobs Act (the “Act”) was enacted in December 2017. The Act reduces the U.S. federal corporate tax rate from 35 percent to 21 percent, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred, creates new taxes on certain foreign earnings and reduces the orphan drug tax credit. In accordance with the Act, the Company determined it necessary to reduce the recorded deferred tax liability by $0.6 million during the nine months ended September 30, 2018 to allow naked credit deferred tax liabilities to be used as a source of taxable income in the future. This change in deferred tax liability has been recognized as income tax benefit in the consolidated financial statements of operations for the nine months ended September 30, 2018 . There was no change in deferred tax liability for the three months ended September 30, 2018 or the three and nine months ended September 30, 2017 . For the nine months ended September 30, 2017 , the Company recorded income tax expense of $0.3 million related to the $2.0 million milestone payments received from Jinghua. No income tax expense was recorded for the three months ended September 30, 2017 or the three and nine months ended September 30, 2018 .

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policy)	9 Months Ended
	Sep. 30, 2018
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company operates in one segment considering the nature of the Company’s products and services, class of customers, methods used to distribute the products and the regulatory environment in which the Company operates.
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The consolidated financial statements include the accounts of Kadmon Holdings, Inc. and its domestic and international subsidiaries, all of which are wholly owned.
Interim Financial Statements	Interim Financial Statements The accompanying financial statements have been prepared in accordance with GAAP for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In management’s opinion, the financial statements include all adjustments (consisting of normal recurring accruals) necessary in order to make the financial statements not misleading. Operating results for the three and nine months ended September 30, 2018 are not necessarily indicative of the final results that may be expected for the year ended December 31, 2018. These unaudited financial statements should be read in conjunction with the audited financial statements in Item 15 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Actual results could differ from those estimates.
Critical Accounting Policies	Critical accounting policies The Company’s significant accounting policies are disclosed in the audited financial statements included in Item 8 of the Annual Report on Form 10-K as of and for the year ended December 31, 2017. Since the date of such financial statements, there have been no changes to the Company’s significant accounting policies, other than those described below.
Investment in Equity Securities	Investment in Equity Securities Equity securities consist of investments in common stock of companies traded on public markets (Note 10). These shares are carried on the Company’s balance sheet at fair value based on the closing price of the shares owned on the last trading day before the balance sheet of this report. Fluctutations in the underlying bid price of the shares result in unrealized gains or losses. In accordance with FASB ASC 321, Investments – Equity Securities (“ASC 321”), the Company recognizes these fluctuations in value as other expense (income). For investments sold, the Company recognizes the gains and losses attributable to these investments as realized gains or losses in other expense (income).
Revenue Recognition	Revenue Recognition The Company adopted FASB ASC 606, Revenue from Contracts with Customers (“ASC 606”), on January 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption – i.e., by recognizing the cumulative effect of initially applying ASC 606 as an adjustment to the opening balance of stockholders’ equity at January 1, 2018. For contracts that were modified before the effective date, the Company reflected the aggregate effect of all modifications when identifying performance obligations and allocating transaction price in accordance with practical expedient ASC 606-10-65-1-(f)-4. The reported results for 2018 reflect the application of ASC 606 guidance while the reported results for 2017 were prepared under the guidance of ASC 605, Revenue Recognition (“ASC 605”), which is also referred to herein as the "previous guidance". The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of the Company's services and will provide financial statement readers with enhanced disclosures. Therefore, the comparative information prior to January 1, 2018 has not been adjusted and continues to be reported under ASC 605. The details of significant changes and quantitative impact of the changes are set out below. The Company recognizes revenue in accordance with ASC 606, the core principle of which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. To achieve this core principle, five basic criteria must be met before revenue can be recognized: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to performance obligations in the contract; and (5) recognize revenue when or as the Company satisfies a performance obligation. Disaggregation of Revenue The following table summarizes revenue from contracts with customers for the three and nine months ended September 30, 2018 (in thousands):    Three Months Ended Nine Months Ended  September 30, 2018 September 30, 2018  Product sales $ 198 $ 633  Other revenue 174 531  Total revenue $ 372 $ 1,164 Product Sales The Company markets a portfolio of branded and generic ribavirin products used as part of a combination treatment for chronic HCV infection (Ribasphere RibaPak and Ribasphere) and also distributes products in a variety of other therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington’s disease. These contracts typically include a single promise to deliver a fixed amount of product to the customer with payment due within 30 days of shipment. Revenues are recognized when control of the promised goods is transferred to the customer, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods. As is typical in the pharmaceutical industry, gross product sales are subject to a variety of deductions, primarily representing rebates, chargebacks, returns, and discounts to government agencies, wholesalers, and managed care organizations. These deductions represent management’s best estimates of the related reserves and, as such, judgment is required when estimating the impact of these sales deductions on gross sales for a reporting period. If estimates are not representative of the actual future settlement, results could be materially affected. Other Revenue The other revenue generated by the Company is primarily related to the transition services agreement and sublease agreement with MeiraGTx Holdings plc (“MeiraGTx”) (Note 10) . The Company performed various professional services under the transition services agreement that support MeiraGTx. The Company recognizes revenue related to transition services and sublease agreements as they are performed. Contract Balances The timing of revenue recognition may differ from the timing of invoicing to customers. Accounts receivable are recorded at the invoiced amount, net of an allowance for doubtful accounts. A receivable is recognized in the period we deliver goods or provide services or when our right to consideration is unconditional. The Company has not recognized any assets for costs to obtain or fulfill a contract with a customer as of September 30, 2018 . Financial Statement Impact of Adopting ASC 606 The Company adopted ASC 606 using the modified retrospective method. The cumulative effect of applying the new guidance to all contracts with customers that were not completed as of January 1, 2018 was recorded as an adjustment to accumulated deficit as of the adoption date as shown in the following table (in thousands):   As Reported Adjustments Adjusted  December 31, AbbVie January 1,  2017 Agreement 2018  (unaudited) (unaudited)  Cash, cash equivalents, and restricted cash $ 69,633 $ $ 69,633  Accounts receivable, net 1,186 1,186  Inventories, net 201 201  Prepaid expenses and other current assets 1,109 1,109  Fixed assets, net 4,292 4,292  Goodwill 3,580 3,580  Investments at cost 3,542 3,542  Other noncurrent assets 9 9  Total assets $ 83,552 $ $ 83,552  Accounts payable and accrued expenses $ 16,585 $ $ 16,585  Fair market value of financial instruments - current 1,952 1,952  Secured term debt - current 33,707 33,707  Deferred revenue, current 4,400 (4,400) —  Deferred revenue, long term 19,617 (19,617) —  Other long term liabilities 5,533 5,533  Total liabilities 81,794 (24,017) 57,777  Common stock, preferred stock, and additional paid-in capital 239,155 239,155  Accumulated deficit (237,397) 24,017 (213,380)  Total stockholders’ equity 1,758 24,017 25,775  Total liabilities and stockholders’ equity $ 83,552 $ — $ 83,552 The year-end condensed balance sheet data was derived from audited consolidated financial statements, but does not include all disclosures required by GAAP. Commercial Partnership Agreement with AbbVie Inc. (“AbbVie”) On June 17, 2013, the Company entered into a series of agreements with AbbVie related to certain of the Company’s ribavirin products. Pursuant to an asset purchase agreement, as amended, the Company sold marketing authorizations and related assets for ribavirin in certain countries outside the United States. The Company received upfront payments totaling $64.0 million, and could have received additional contingent payments totaling $51.0 million based on the achievement of certain milestones. The Company did not earn any such milestones during the nine months ended September 30, 2018 . Of the $64.0 million upfront payments, $44.0 million was considered allocable to the domestic licensing arrangement and was recorded as deferred revenue to be recognized over the 10 year term of the agreement. The Company recognized $1.1 million and $3.3 million during the three and nine months ended September 30, 2017 , respectively. At December 31, 2017, $24.0 million was recorded as deferred revenue, of which $4.4 million was short ‑term. The Company is required to supply ribavirin products, maintain the marketing authorization for certain ribavirin products and maintain the intellectual property for Ribasphere and RibaPak through the term of the agreements ending December 31, 2020. The Company’s agreements with AbbVie provide AbbVie with access to various forms of intellectual property, as well as supply of product. Under the previous guidance, certain of the upfront payments under the agreements were considered allocable to a 10-year domestic license arrangement and, as a result, the associated revenue was previously deferred and recognized straight line over the life of the agreements. Under ASC 606, the Company has determined that two distinct performance obligations under the domestic license agreement exist, both of which are considered to be completed as of the date of adoption. No other material rights or enforceable rights or obligations exist under the AbbVie agreements. In conjunction with the January 1, 2018 adoption of ASC 606, the Company adjusted its accumulated deficit by $24.0 million, reflecting the recognition of $24.0 million of deferred revenue related to the domestic license agreement with AbbVie. Income Taxes The adoption of ASC 606 primarily resulted in an acceleration of revenue as of January 1, 2018, which in turn generated additional deferred tax liabilities that ultimately reduced the Company's net deferred tax asset position. As the Company fully reserves its net deferred tax assets in the jurisdictions impacted by the adoption of ASC 606, this impact was offset by a corresponding reduction to the valuation allowance. Impact of New Revenue Guidance on Financial Statement Line Items The following table compares the reported condensed consolidated balance sheet as of September 30, 2018 to the pro-forma amounts had the previous guidance been in effect (in thousands):   As Reported Balances without adoption of ASC 606  September 30, 2018 Adjustments September 30, 2018 December 31, 2017  (unaudited) (unaudited) (unaudited)  Cash, cash equivalents, and restricted cash $ 115,467 $ $ 115,467 $ 69,633  Accounts receivable, net 979 979 1,186  Inventories, net 1,063 1,063 201  Investment, equity securities 48,072 48,072 —  Prepaid expenses and other current assets 2,225 2,225 1,109  Fixed assets, net 4,027 4,027 4,292  Goodwill 3,580 3,580 3,580  Investment, at cost 2,300 2,300 3,542  Other noncurrent assets 2 2 9  Total assets $ 177,715 $ — $ 177,715 $ 83,552  Accounts payable and accrued expenses $ 16,460 $ $ 16,460 $ 16,585  Fair market value of financial instruments - current 1,247 1,247 1,952  Secured term debt - current — — 33,707  Deferred revenue, current — 4,400 4,400 4,400  Deferred revenue, long term — 16,317 16,317 19,617  Other long term liabilities 4,740 4,740 5,533  Secured term debt – net of current portion and discount 27,386 27,386 —  Total liabilities 49,833 20,717 70,550 81,794  Common stock, preferred stock, and additional paid-in capital 355,493 355,493 239,155  Accumulated deficit (227,611) (20,717) (248,328) (237,397)  Total stockholders’ equity (deficit) 127,882 (20,717) 107,165 1,758  Total liabilities and stockholders’ equity $ 177,715 $ — $ 177,715 $ 83,552 The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. Total reported liabilities were $20.7 million less than the pro-forma balance sheet, which assumes the Company had continued to recognize revenues under ASC 605 as of September 30, 2018 . This is due to the recognition of the deferred revenue related to the AbbVie agreement upon adoption of ASC 606. The following summarizes the significant changes on the Company’s condensed consolidated statement of operations for the three months ended September 30, 2018 as a result of the adoption of ASC 606 on January 1, 2018, which assumes the Company had continued to recognize revenues under ASC 605 (in thousands, except share and per share amounts):    As Reported Three Months Ended Balances without adoption of ASC 606 Three Months Ended  September 30, 2018 Adjustments September 30, 2018 September 30, 2017  (unaudited) (unaudited) (unaudited) (unaudited)  Net sales $ 198 $ $ 198 $ 1,036  License and other revenue 174 1,100 1,274 1,241  Total revenue 372 1,100 1,472 2,277  Cost of sales and write-down of inventory 79 79 1,210  Research and development 11,918 11,918 11,775  Selling, general and administrative 9,668 9,668 9,121  Total other expense (income) (7,494) (7,494) 1,874  Net income (loss) attributable to common stockholders $ (13,799) $ 1,100 $ (12,699) $ (21,703)  Deemed dividend on convertible preferred stock 515 515 490  Net income (loss) attributable to common stockholders $ (14,314) $ 1,100 $ (13,214) $ (22,193)   Basic and diluted net income (loss) per share of common stock $ (0.13) $ 0.01 $ (0.12) $ (0.42)  Weighted average basic and diluted shares of common stock outstanding 113,101,776 113,101,776 113,101,776 52,572,880 The following summarizes the significant changes on the Company’s condensed consolidated statement of operations for the nine months ended September 30, 2018 as a result of the adoption of ASC 606 on January 1, 2018, which assumes the Company had continued to recognize revenues under ASC 605 (in thousands, except share and per share amounts):    As Reported Nine Months Ended Balances without adoption of ASC 606 Nine Months Ended  September 30, 2018 Adjustments September 30, 2018 September 30, 2017  (unaudited) (unaudited) (unaudited) (unaudited)  Net sales $ 633 $ $ 633 $ 5,070  License and other revenue 531 3,300 3,831 5,730  Total revenue 1,164 3,300 4,464 10,800  Cost of sales and write-down of inventory 626 626 2,786  Research and development 31,876 31,876 30,278  Selling, general and administrative 26,730 26,730 29,141  Total other expense (income) (44,771) (44,771) 9,863  Income tax expense (benefit) (562) (562) 316  Net income (loss) attributable to common stockholders $ (12,735) $ 3,300 $ (9,435) $ (61,584)  Deemed dividend on convertible preferred stock 1,496 1,496 1,428  Net income (loss) attributable to common stockholders $ (14,231) $ 3,300 $ (10,931) $ (63,012)   Basic and diluted net income (loss) per share of common stock $ (0.15) $ 0.04 $ (0.11) $ (1.25)  Weighted average basic and diluted shares of common stock outstanding 92,378,205 92,378,205 92,378,205 50,331,163 The Company’s adoption of ASC 606 accelerated the recognition of revenue that was previously deferred under the AbbVie domestic license agreement, resulting in a cumulative effect adjustment to accumulated deficit on January 1, 2018. Therefore no further revenue will be recognized under the AbbVie domestic license agreement. Revenue under this agreement had previously been recognized under license and other revenue. The adoption of ASC 606 had no impact on the Company’s cash flows from operations. The aforementioned adjustments resulted in offsetting shifts in cash flows to net loss and change in deferred revenue. Transaction Price Allocated to Future Performance Obligations ASC 606 requires that the Company disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of September 30, 2018 . The guidance provides certain practical expedients that limit this requirement. The Company has various contracts that meet the following practical expedients provided by ASC 606: 1. The performance obligation is part of a contract that has an original expected duration of one year or less. 2. Revenue is recognized from the satisfaction of the performance obligations in the amount billable to the customer. 3. The variable consideration is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation. The Company does not have any performance obligations, outside of the practical expedients above, that have not yet been satisfied as of September 30, 2018 and therefore there is no transaction price allocated to future performance obligations under ASC 606.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2018-15, “ I ntangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force)” , which requires customers in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in Accounting Standards Codification 350-40 to determine which implementation costs to capitalize as assets. This ASU is effective for annual or any interim periods beginning after December 15, 2019. The Company does not expect the standard to have a significant impact on its consolidated financial statements, as the Company’s cloud computing contracts are not material. In June 2018, the FASB issued ASU No. 2018-07, “ Compensation – Stock Compensation” , which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees, except for specific exceptions. This ASU is effective for annual or any interim periods beginning after December 15, 2018. The Company does not expect the standard to have a significant impact on its consolidated financial statements, as the fair value of the Company’s awards to nonemployees is immaterial . In May 2017, the FASB issued ASU No. 2017-09, “ Compensation – Stock Compensation” , which clarifies the guidance about which changes to the terms and conditions of a share-based payments award require an entity to apply modification accounting in Topic 718. This ASU is effective for annual or any interim periods beginning after December 15, 2017. The Company adopted this standard on January 1, 2018, which did not impact the consolidated finan cial statements as the Company has not modified the terms and conditions of any share-based payments during the year ended December 31, 2017 or the nine months ended September 30, 2018 . In January 2017, the FASB issued ASU No. 2017-04, “ Intangibles – Goodwill and Other” , which simplifies the subsequent measurement of goodwill by eliminating “Step 2” from the goodwill impairment test. Instead of performing Step 2 to determine the amount of an impairment charge, the fair value of a reporting unit will be compared with its carrying amount and an impairment charge will be recognized for the value by which the carrying amount exceeds the reporting unit’s fair value. ASU 2017-04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company does not expect the standard to have a significant impact on its consolidated financial statements . In November 2016, the FASB issued ASU No. 2016-18, “ Statement of Cash Flows (Topic 230): Restricted Cash ”. This ASU requires that the statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Entities will also be required to reconcile such total amounts on the balance sheet and disclose the nature of the restrictions. The Company adopted this standard on January 1, 2018, which did not have a significant impact on its consolidated financial statements as the Company’s restricted cash balances are immaterial. In February 2016, the FASB issued ASU No. 2016 ‑02, “ Leases ”. This ASU amends the existing accounting standards for lease accounting, including requiring lessees to recognize most leases on their balance sheets. Current GAAP does not require lessees to recognize assets and liabilities arising from operating leases on the balance sheet. This guidance is effective for annual and interim reporting periods of public entities beginning after December 15, 2018, with early adoption permitted. In July 2018, the FASB issued ASU No. 2018-10, “Codification Improvements to Topic 842, Leases” and ASU 2018-11, “Leases (Topic 842): Targeted Improvements” . These ASU’s make improvements and provide clarity to several aspects of the guidance in ASC 842. The Company is in the process of implementation and expects to adopt this guidance when it becomes effective using the optional transition method allowed under the standard which does not require comparative periods to be restated. The Company expects to elect to apply practical expedients allowed under the standard, which, among other things, allows the carryforward of historical lease classifications. The Company expects that adoption of this standard will have a material impact on the Company’s consolidated balance sheets and related disclosures, as a result of recognizing a cumulative-effect adjustment reflecting right-of-use assets and lease liabilities related to its operating leases on January 1, 2019

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2018
Summary of Significant Accounting Policies [Abstract]
Disaggregation of Revenue	  Three Months Ended Nine Months Ended  September 30, 2018 September 30, 2018  Product sales $ 198 $ 633  Other revenue 174 531  Total revenue $ 372 $ 1,164 
Adoption of New Accounting Pronouncements	  As Reported Adjustments Adjusted  December 31, AbbVie January 1,  2017 Agreement 2018  (unaudited) (unaudited)  Cash, cash equivalents, and restricted cash $ 69,633 $ $ 69,633  Accounts receivable, net 1,186 1,186  Inventories, net 201 201  Prepaid expenses and other current assets 1,109 1,109  Fixed assets, net 4,292 4,292  Goodwill 3,580 3,580  Investments at cost 3,542 3,542  Other noncurrent assets 9 9  Total assets $ 83,552 $ $ 83,552  Accounts payable and accrued expenses $ 16,585 $ $ 16,585  Fair market value of financial instruments - current 1,952 1,952  Secured term debt - current 33,707 33,707  Deferred revenue, current 4,400 (4,400) —  Deferred revenue, long term 19,617 (19,617) —  Other long term liabilities 5,533 5,533  Total liabilities 81,794 (24,017) 57,777  Common stock, preferred stock, and additional paid-in capital 239,155 239,155  Accumulated deficit (237,397) 24,017 (213,380)  Total stockholders’ equity 1,758 24,017 25,775  Total liabilities and stockholders’ equity $ 83,552 $ — $ 83,552 
Initial Application Period Cumulative Effect Transition on Balance Sheet	  As Reported Balances without adoption of ASC 606  September 30, 2018 Adjustments September 30, 2018 December 31, 2017  (unaudited) (unaudited) (unaudited)  Cash, cash equivalents, and restricted cash $ 115,467 $ $ 115,467 $ 69,633  Accounts receivable, net 979 979 1,186  Inventories, net 1,063 1,063 201  Investment, equity securities 48,072 48,072 —  Prepaid expenses and other current assets 2,225 2,225 1,109  Fixed assets, net 4,027 4,027 4,292  Goodwill 3,580 3,580 3,580  Investment, at cost 2,300 2,300 3,542  Other noncurrent assets 2 2 9  Total assets $ 177,715 $ — $ 177,715 $ 83,552  Accounts payable and accrued expenses $ 16,460 $ $ 16,460 $ 16,585  Fair market value of financial instruments - current 1,247 1,247 1,952  Secured term debt - current — — 33,707  Deferred revenue, current — 4,400 4,400 4,400  Deferred revenue, long term — 16,317 16,317 19,617  Other long term liabilities 4,740 4,740 5,533  Secured term debt – net of current portion and discount 27,386 27,386 —  Total liabilities 49,833 20,717 70,550 81,794  Common stock, preferred stock, and additional paid-in capital 355,493 355,493 239,155  Accumulated deficit (227,611) (20,717) (248,328) (237,397)  Total stockholders’ equity (deficit) 127,882 (20,717) 107,165 1,758  Total liabilities and stockholders’ equity $ 177,715 $ — $ 177,715 $ 83,552 
Initial Application Period Cumulative Effect Transition on Income Statement	   As Reported Three Months Ended Balances without adoption of ASC 606 Three Months Ended  September 30, 2018 Adjustments September 30, 2018 September 30, 2017  (unaudited) (unaudited) (unaudited) (unaudited)  Net sales $ 198 $ $ 198 $ 1,036  License and other revenue 174 1,100 1,274 1,241  Total revenue 372 1,100 1,472 2,277  Cost of sales and write-down of inventory 79 79 1,210  Research and development 11,918 11,918 11,775  Selling, general and administrative 9,668 9,668 9,121  Total other expense (income) (7,494) (7,494) 1,874  Net income (loss) attributable to common stockholders $ (13,799) $ 1,100 $ (12,699) $ (21,703)  Deemed dividend on convertible preferred stock 515 515 490  Net income (loss) attributable to common stockholders $ (14,314) $ 1,100 $ (13,214) $ (22,193)   Basic and diluted net income (loss) per share of common stock $ (0.13) $ 0.01 $ (0.12) $ (0.42)  Weighted average basic and diluted shares of common stock outstanding 113,101,776 113,101,776 113,101,776 52,572,880 The following summarizes the significant changes on the Company’s condensed consolidated statement of operations for the nine months ended September 30, 2018 as a result of the adoption of ASC 606 on January 1, 2018, which assumes the Company had continued to recognize revenues under ASC 605 (in thousands, except share and per share amounts):    As Reported Nine Months Ended Balances without adoption of ASC 606 Nine Months Ended  September 30, 2018 Adjustments September 30, 2018 September 30, 2017  (unaudited) (unaudited) (unaudited) (unaudited)  Net sales $ 633 $ $ 633 $ 5,070  License and other revenue 531 3,300 3,831 5,730  Total revenue 1,164 3,300 4,464 10,800  Cost of sales and write-down of inventory 626 626 2,786  Research and development 31,876 31,876 30,278  Selling, general and administrative 26,730 26,730 29,141  Total other expense (income) (44,771) (44,771) 9,863  Income tax expense (benefit) (562) (562) 316  Net income (loss) attributable to common stockholders $ (12,735) $ 3,300 $ (9,435) $ (61,584)  Deemed dividend on convertible preferred stock 1,496 1,496 1,428  Net income (loss) attributable to common stockholders $ (14,231) $ 3,300 $ (10,931) $ (63,012)   Basic and diluted net income (loss) per share of common stock $ (0.15) $ 0.04 $ (0.11) $ (1.25)  Weighted average basic and diluted shares of common stock outstanding 92,378,205 92,378,205 92,378,205 50,331,163 

Net Income (Loss) per Share Att

Net Income (Loss) per Share Attributable to Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2018
Net Loss per Share Attributable to Common Stockholders [Abstract]
Computation of Basic and Diluted Net Income (Loss) per Share Attributable to Common Stockholders	  Three Months Ended Nine Months Ended  September 30, September 30,  2018 2017 2018 2017  Numerator – basic and diluted:  Net loss available to common stockholders $ (14,314) $ (22,193) $ (14,231) $ (63,012)  Denominator – basic and diluted:  Weighted average common shares outstanding used to compute basic and diluted net loss per share 113,101,776 52,572,880 92,378,205 50,331,163  Net loss per share, basic and diluted $ (0.13) $ (0.42) $ (0.15) $ (1.25) 
Anti-dilutive Amounts Excluded From Calculation of Diluted Net Income (Loss) per Share	   Three Months Ended Nine Months Ended  September 30, September 30,  2018 2017 2018 2017  Options to purchase common stock 9,713,427 3,310,843 9,713,427 3,310,843  Warrants to purchase common stock 11,999,852 6,067,447 11,999,852 6,067,447  Convertible preferred stock 3,476,385 12,945,590 3,476,385 12,945,590  Total shares of common stock equivalents 25,189,664 22,323,880 25,189,664 22,323,880 

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2018
Debt [Abstract]
Debt Payable	   September 30, December 31,  2018 2017   Secured term debt due July 1, 2020 $ 28,046 $ 34,620   Total debt before fees, interest and debt discount/premium 28,046 34,620  Less: Deferred financing costs — (228)  Debt discount (660) (1,030)  Add: Debt premium — 345  Total debt payable $ 27,386 $ 33,707   Debt payable, current portion $ — $ 33,707  Debt payable, long-term $ 27,386 $ — 
Minimum Payments Required on Outstanding Balances	   2015 Credit Agreement  2018 $ —  2019 —  2020 28,046  $ 28,046 
Interest Expense and Other Related Financing Costs	   Three Months Ended Nine Months Ended  September 30, September 30,  2018 2017 2018 2017  Interest expense and other financing costs $ 830 $ 955 $ 2,720 $ 2,772  Amortization of deferred financing costs, debt discount and debt premium 47 514 960 1,727  Interest expense $ 877 $ 1,469 $ 3,680 $ 4,499 

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2018
Financial Instruments [Abstract]
Fair Values of Financial Instruments	   Fair Value Measurement Using Significant Other Observable Inputs (Level 2)   September 30, December 31,  Description 2018 2017  Warrants $ 1,247 $ 1,952  Total $ 1,247 $ 1,952 
Rollforward of Level 2 Investments	   Significant Other Observable Inputs  (Level 2)  Balance at January 1, 2017 $ 3,305  Fair value of warrants modified in the Third Amendment (908)  Issuance of warrants in private placement 1,651  Change in fair value of financial instruments (2,096)  Balance at December 31, 2017 $ 1,952  Change in fair value of financial instruments (802)  Fair value of warrants modified in the Fifth Amendment 111  Exercise of warrants recorded as liability (14)  Balance at September 30, 2018 $ 1,247 
Warrants Outstanding	   Warrants Weighted Average Exercise Price  Balance, December 31, 2017 14,722,790 $ 5.70  Granted — —  Exercised (134,847) 4.21  Forfeited (2,588,091) 4.50  Balance, September 30, 2018 11,999,852 $ 5.97 

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2018
Inventories [Abstract]
Schedule of Inventories	   September 30, December 31,  2018 2017  Work-in-process 1,032 80  Finished goods, net 31 121  Total inventories $ 1,063 $ 201 

Fixed Assets (Tables)

Fixed Assets (Tables)	9 Months Ended
	Sep. 30, 2018
Fixed Assets [Abstract]
Fixed Assets	   Useful Lives September 30, December 31,  (Years) 2018 2017   Leasehold improvements 4 -8 $ 10,187 $ 10,120  Office equipment and furniture 3 -15 1,529 1,488  Machinery and laboratory equipment 3 -15 3,242 2,765  Software 1 -5 3,624 3,162  Construction-in-progress ̶̶̶̶ 201 408  18,783 17,943  Less accumulated depreciation and amortization (14,756) (13,651)  Fixed assets, net $ 4,027 $ 4,292 

Share-based Compensation (Table

Share-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Share-based Compensation [Abstract]
Stock Options Outstanding	   Options Outstanding  Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term (years) Aggregate Intrinsic Value (in thousands)  Balance, December 31, 2017 8,496,872 $ 6.96 8.83 $ —  Granted 280,924 4.62  Exercised — —  Forfeited (661,869) 4.78  Balance, September 30, 2018 8,115,927 $ 7.06 8.08 $ —  Options vested and exercisable, September 30, 2018 4,271,886 $ 9.69 7.37 $ — 
Weighted-average Fair Value of Stock Option Awards Granted	   Nine Months Ended Nine Months Ended  September 30, 2018 September 30, 2017  Weighted average fair value of grants $2.20 $2.62  Expected volatility 72.94% - 75.14% 74.48% -74.70%  Risk-free interest rate 2.44% - 2.84% 1.87% -2.00%  Expected life (years) 5.50 - 6.00 5.50 -5.75  Expected dividend yield 0% 0% 

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2018
Accrued Expenses [Abstract]
Short-term Accrued Expenses	   September 30, December 31,  2018 2017  Commission payable $ 2,395 $ 2,395  Compensation and benefits 408 758  Severance 569 1,122  Research and development 3,229 1,915  Other 2,913 2,387  Total Accrued Expenses $ 9,514 $ 8,577 

Organization (Narrative) (Detai

Organization (Narrative) (Details) - USD ($)	Jun. 18, 2018	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Aug. 15, 2018	Jan. 01, 2018	Dec. 31, 2017
Accumulated deficit			$ (227,611,000)			$ (213,380,000)	$ (237,397,000)
Working capital			99,900,000
Cash and cash equivalents			113,351,000	$ 73,605,000			$ 67,517,000
Net proceeds from common stock			$ 105,761,000	$ 83,861,000
Common stock issued			113,101,776				78,643,954
2015 Credit Agreement, Third Amendment [Member]
Warrants exercise price					$ 4.50
Warrants outstanding					$ 88,238
2015 Credit Agreement, Fifth Amendment [Member]
Deferred principal payments					$ 750,000
Warrants exercise price					$ 3.30
Expected proceeds if warrants are exercised			$ 2,100,000
Warrants outstanding					$ 529,413
2017 Public Offering [Member]
Warrants exercise price				$ 3.35
2018 Public Offering [Member]
Gross proceeds from common stock		$ 113,200,000
Net proceeds from common stock		105,800,000
Underwriting discounts and commissions		$ 7,400,000
Common stock issued		34,303,030
Price per share of common stock		$ 3.30
Secured Term Debt [Member] | 2015 Credit Agreement, Third Amendment [Member]
Deferred principal payments				$ 380,000
Warrants exercise price			$ 4.50
Secured Term Debt [Member] | 2015 Credit Agreement, Fourth Amendment [Member]
Debt repaid	$ 4,700,000	$ 4,700,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Narrative) (Details)	Jun. 17, 2013USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)segmentitem	Sep. 30, 2017USD ($)	Jan. 01, 2018USD ($)	Dec. 31, 2017USD ($)
Summary Of Significant Accounting Policies [Line Items]
Number of operating segments | segment				1
Cost of sales and write-down of inventory		$ 79,000	$ 1,210,000	$ 626,000	$ 2,786,000
Accumulated deficit		227,611,000		227,611,000		$ 213,380,000	$ 237,397,000
Deferred revenue, current							4,400,000
Liabilities		49,833,000		49,833,000		57,777,000	81,794,000
Revenues		372,000	2,277,000	1,164,000	10,800,000
Adjustments [Member]
Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit		20,717,000		20,717,000		(24,017,000)
Deferred revenue, current		4,400,000		4,400,000		(4,400,000)
Liabilities		20,717,000		20,717,000		$ (24,017,000)
Revenues		1,100,000		3,300,000
Balances Without Adoption of ASC 606 [Member]
Summary Of Significant Accounting Policies [Line Items]
Cost of sales and write-down of inventory		79,000		626,000
Accumulated deficit		248,328,000		248,328,000
Deferred revenue, current		4,400,000		4,400,000
Liabilities		70,550,000		70,550,000
Revenues		$ 1,472,000		$ 4,464,000
AbbVie, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of performance obligations | item				2
Upfront Payment	$ 64,000,000
Contingent milestone payments	51,000,000
Deferred Revenue	$ 44,000,000						24,000,000
License agreement, term				10 years
License revenue			$ 1,100,000		$ 3,300,000
Deferred revenue, current							$ 4,400,000
Revenues				$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Disaggregation of Revenue) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues	$ 372,000	$ 2,277,000	$ 1,164,000	$ 10,800,000
Product Sales [Member]
Revenues	198,000		633,000
Other Revenue [Member]
Revenues	$ 174,000		$ 531,000

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Adoption of New Accounting Pronouncements) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Cash, cash equivalents, and restricted cash	$ 115,467	$ 69,633	$ 69,633	$ 75,721	$ 38,209
Accounts receivable, net	979	1,186	1,186
Inventories, net	1,063	201	201
Prepaid expenses and other current assets	2,225	1,109	1,109
Fixed assets, net	4,027	4,292	4,292
Goodwill	3,580	3,580	3,580
Investment, at cost	2,300	3,542	3,542
Other noncurrent assets	2	9	9
Total assets	177,715	83,552	83,552
Accounts payable and accrued expenses	16,460	16,585	16,585
Fair market value of financial instruments - current	1,247	1,952	1,952
Secured term debt - current		33,707	33,707
Deferred revenue, current			4,400
Deferred revenue, long term			19,617
Other long term liabilities	4,740	5,533	5,533
Total liabilities	49,833	57,777	81,794
Common stock, preferred stock, and additional paid-in capital	355,493	239,155	239,155
Accumulated deficit	(227,611)	(213,380)	(237,397)
Total stockholders’ equity	127,882	25,775	1,758
Total liabilities and stockholders’ equity	177,715	83,552	$ 83,552
Adjustments [Member]
Deferred revenue, current	4,400	(4,400)
Deferred revenue, long term	16,317	(19,617)
Total liabilities	20,717	(24,017)
Accumulated deficit	(20,717)	24,017
Total stockholders’ equity	(20,717)	$ 24,017
Balances Without Adoption of ASC 606 [Member]
Cash, cash equivalents, and restricted cash	115,467
Accounts receivable, net	979
Inventories, net	1,063
Prepaid expenses and other current assets	2,225
Fixed assets, net	4,027
Goodwill	3,580
Investment, at cost	2,300
Other noncurrent assets	2
Total assets	177,715
Accounts payable and accrued expenses	16,460
Fair market value of financial instruments - current	1,247
Deferred revenue, current	4,400
Deferred revenue, long term	16,317
Other long term liabilities	4,740
Total liabilities	70,550
Common stock, preferred stock, and additional paid-in capital	355,493
Accumulated deficit	(248,328)
Total stockholders’ equity	107,165
Total liabilities and stockholders’ equity	$ 177,715

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Initial Application Period Cumulative Effect Transition on Balance Sheet) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017	Sep. 30, 2017	Dec. 31, 2016
Cash, cash equivalents, and restricted cash	$ 115,467	$ 69,633	$ 69,633	$ 75,721	$ 38,209
Accounts receivable, net	979	1,186	1,186
Inventories, net	1,063	201	201
Investment, equity securities	48,072
Prepaid expenses and other current assets	2,225	1,109	1,109
Fixed assets, net	4,027	4,292	4,292
Goodwill	3,580	3,580	3,580
Investment, at cost	2,300	3,542	3,542
Other noncurrent assets	2	9	9
Total assets	177,715	83,552	83,552
Accounts payable and accrued expenses	16,460	16,585	16,585
Fair market value of financial instruments - current	1,247	1,952	1,952
Secured term debt - current		33,707	33,707
Deferred revenue, current			4,400
Deferred revenue, long term			19,617
Other long term liabilities	4,740	5,533	5,533
Secured term debt – net of current portion and discount	27,386
Total liabilities	49,833	57,777	81,794
Common stock, preferred stock, and additional paid-in capital	355,493	239,155	239,155
Accumulated deficit	(227,611)	(213,380)	(237,397)
Total stockholders’ equity	127,882	25,775	1,758
Total liabilities and stockholders’ equity	177,715	83,552	$ 83,552
Adjustments [Member]
Deferred revenue, current	4,400	(4,400)
Deferred revenue, long term	16,317	(19,617)
Total liabilities	20,717	(24,017)
Accumulated deficit	(20,717)	24,017
Total stockholders’ equity	(20,717)	$ 24,017
Balances Without Adoption of ASC 606 [Member]
Cash, cash equivalents, and restricted cash	115,467
Accounts receivable, net	979
Inventories, net	1,063
Investment, equity securities	48,072
Prepaid expenses and other current assets	2,225
Fixed assets, net	4,027
Goodwill	3,580
Investment, at cost	2,300
Other noncurrent assets	2
Total assets	177,715
Accounts payable and accrued expenses	16,460
Fair market value of financial instruments - current	1,247
Deferred revenue, current	4,400
Deferred revenue, long term	16,317
Other long term liabilities	4,740
Secured term debt – net of current portion and discount	27,386
Total liabilities	70,550
Common stock, preferred stock, and additional paid-in capital	355,493
Accumulated deficit	(248,328)
Total stockholders’ equity	107,165
Total liabilities and stockholders’ equity	$ 177,715

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Initial Application Period Cumulative Effect Transition on Income Statement) (Details) - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Total revenue	$ 372,000			$ 2,277,000	$ 1,164,000	$ 10,800,000
Cost of sales and write-down of inventory	79,000			1,210,000	626,000	2,786,000
Research and development	11,918,000			11,775,000	31,876,000	30,278,000
Selling, general and administrative	9,668,000			9,121,000	26,730,000	29,141,000
Total other expense (income)	(7,494,000)			1,874,000	(44,771,000)	9,863,000
Income tax expense (benefit)					(562,000)	316,000
Net loss	(13,799,000)	$ 21,505,000	$ (20,441,000)	(21,703,000)	(12,735,000)	(61,584,000)
Deemed dividend on convertible preferred stock	515,000			490,000	1,496,000	1,428,000
Net loss attributable to common stockholders	$ (14,314,000)			$ (22,193,000)	$ (14,231,000)	$ (63,012,000)
Basic net income (loss) per share of common stock	$ (0.13)			$ (0.42)	$ (0.15)	$ (1.25)
Diluted net income (loss) per share of common stock	$ 113,101,776			$ 52,572,880	$ 92,378,205	$ 50,331,163
Net Sales [Member]
Total revenue	$ 198,000			$ 1,036,000	$ 633,000	$ 5,070,000
License and Other Revenue [Member]
Total revenue	174,000			$ 1,241,000	531,000	$ 5,730,000
Adjustments [Member]
Total revenue	1,100,000				3,300,000
Net loss	1,100,000				3,300,000
Net loss attributable to common stockholders	$ 1,100,000				$ 3,300,000
Basic net income (loss) per share of common stock	$ 0.01				$ 0.04
Diluted net income (loss) per share of common stock	$ 113,101,776				$ 92,378,205
Adjustments [Member] | License and Other Revenue [Member]
Total revenue	$ 1,100,000				$ 3,300,000
Balances Without Adoption of ASC 606 [Member]
Total revenue	1,472,000				4,464,000
Cost of sales and write-down of inventory	79,000				626,000
Research and development	11,918,000				31,876,000
Selling, general and administrative	9,668,000				26,730,000
Total other expense (income)	(7,494,000)				(44,771,000)
Income tax expense (benefit)					(562,000)
Net loss	(12,699,000)				(9,435,000)
Deemed dividend on convertible preferred stock	515,000				1,496,000
Net loss attributable to common stockholders	$ (13,214,000)				$ (10,931,000)
Basic net income (loss) per share of common stock	$ (0.12)				$ (0.11)
Diluted net income (loss) per share of common stock	$ 113,101,776				$ 92,378,205
Balances Without Adoption of ASC 606 [Member] | Net Sales [Member]
Total revenue	$ 198,000				$ 633,000
Balances Without Adoption of ASC 606 [Member] | License and Other Revenue [Member]
Total revenue	$ 1,274,000				$ 3,831,000

Stockholders_ Equity (Narrative

Stockholders’ Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2014	Dec. 31, 2017
Beneficial conversion feature on convertible preferred stock					$ 299	$ 286
Accrued dividends on preferred stock					$ 1,197	1,142
IPO price per share					$ 12
Common stock, par value	$ 0.001				$ 0.001			$ 0.001
Common stock, shares authorized	200,000,000				200,000,000			200,000,000
Class E Redeemable Convertible Units [Member]
Transaction costs							$ 3,100
Stock issued, shares							3,514,859
Convertible Preferred Stock [Member]
Preferred stock outstanding	30,000				30,000			30,000
Convertible preferred stock rate					5.00%
Accrued dividends added to liquidation preference			$ 1,600	$ 1,400
Liquidation preference	$ 33,000				$ 33,000
Beneficial conversion feature, discount percentage					20.00%
Accrued dividends on preferred stock	400	$ 300			$ 1,200	1,100
Deemed dividends on preferred stock	$ 100	$ 100			$ 300	$ 300

Net Loss per Share Attributab_2

Net Loss per Share Attributable to Common Stockholders (Computation of Basic and Diluted Net Income (Loss) per Share Attributable to Common Stockholders) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net Loss per Share Attributable to Common Stockholders [Abstract]
Net loss available to common stockholders	$ (14,314)	$ (22,193)	$ (14,231)	$ (63,012)
Weighted average common shares outstanding used to compute basic and diluted net loss per share	113,101,776	52,572,880	92,378,205	50,331,163
Net loss per share, basic and diluted	$ (0.13)	$ (0.42)	$ (0.15)	$ (1.25)

Net Loss per Share Attributab_3

Net Loss per Share Attributable to Common Stockholders (Anti-dilutive Amounts Excluded From Calculation of Diluted Net Income (Loss) per Share) (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares of common stock equivalents	25,189,664	22,323,880	25,189,664	22,323,880
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares of common stock equivalents	9,713,427	3,310,843	9,713,427	3,310,843
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares of common stock equivalents	11,999,852	6,067,447	11,999,852	6,067,447
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares of common stock equivalents	3,476,385	12,945,590	3,476,385	12,945,590

Debt (Narrative) (Details)

Debt (Narrative) (Details)	Jun. 18, 2018USD ($)	Jun. 30, 2018USD ($)	Aug. 31, 2015USD ($)item	Sep. 30, 2018USD ($)$ / shares	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	Aug. 31, 2018USD ($)	Aug. 15, 2018USD ($)$ / shares	Dec. 31, 2017USD ($)
Debt Instrument [Line Items]
Debt discount				$ 660,000		$ 660,000				$ 1,030,000
Debt Instrument, Unamortized Premium										345,000
Deferred financing costs										228,000
Warrants to purchase						10,671,400
2015 Credit Agreement, Third Amendment [Member]
Debt Instrument [Line Items]
Interest expense				0	$ 200,000	$ 0
Warrants exercise price | $ / shares									$ 4.50
Warrants outstanding									$ 88,238
2015 Credit Agreement, Fifth Amendment [Member]
Debt Instrument [Line Items]
Maturity date						Jul. 1, 2020
Debt discount								$ 100,000	700,000
Interest expense				100,000		$ 100,000
Deferred principal payments									$ 750,000
Warrants exercise price | $ / shares									$ 3.30
Expected proceeds if warrants are exercised						2,100,000
Warrants outstanding									$ 529,413
Secured Term Debt [Member] | 2015 Credit Agreement [Member]
Debt Instrument [Line Items]
Total borrowings			$ 35,000,000
Commitment Fee			$ 800,000
Monthly principal payments						380,000
Number of lenders | item			2
Deferred financing costs				1,300,000		1,300,000
Unamortized deferred financing costs				0		$ 0				$ 200,000
Debt term						3 years
Interest expense				0	100,000	$ 200,000	$ 400,000
Deferred principal payments				380,000		380,000
Additional equity capital to be raised				$ 40,000,000		$ 40,000,000
Warrants exercise price | $ / shares				$ 10.20		$ 10.20
Secured Term Debt [Member] | 2015 Credit Agreement [Member] | Class A Warrants [Member]
Debt Instrument [Line Items]
Debt discount			$ 5,400,000	$ 5,400,000		$ 5,400,000
Loss on extinguishment of debt			900,000			900,000
Warrants to purchase			$ 6,300,000			6,300,000
Secured Term Debt [Member] | 2015 Credit Agreement, Third Amendment [Member]
Debt Instrument [Line Items]
Debt Instrument, Unamortized Premium					900,000		900,000
Interest expense						$ 300,000	400,000
Deferred principal payments					380,000		380,000
Additional equity capital to be raised					$ 17,000,000		$ 17,000,000
Warrants issued | shares						617,651
Warrants exercise price | $ / shares				$ 4.50		$ 4.50
Secured Term Debt [Member] | 2015 Credit Agreement, Fourth Amendment [Member]
Debt Instrument [Line Items]
Debt repaid	$ 4,700,000	$ 4,700,000
Secured Term Debt [Member] | London Interbank Offered Rate (LIBOR) [Member] | 2015 Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument spread			9.375%
Secured Term Debt [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member] | 2015 Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument spread			1.00%

Debt (Debt Payable) (Details)

Debt (Debt Payable) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Total debt before fees, interest and debt discount/premium	$ 28,046	$ 34,620
Less: Deferred financing costs		(228)
Debt discount	(660)	(1,030)
Add: Debt premium		345
Total debt payable	27,386	33,707
Debt payable, current portion		33,707
Debt payable, long-term	27,386
Secured Term Debt Due August 31, 2018 [Member] | Secured Term Debt [Member]
Debt Instrument [Line Items]
Total debt before fees, interest and debt discount/premium	$ 28,046	$ 34,620
Maturity date	Jul. 1, 2020

Debt (Minimum Payments Required

Debt (Minimum Payments Required on Outstanding Balances) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Total debt payable	$ 27,386	$ 33,707
2015 Credit Agreement [Member]
Debt Instrument [Line Items]
2,018
2,019
2,020	28,046
Total debt payable	$ 28,046

Debt (Interest Expense and Othe

Debt (Interest Expense and Other Related Financing Costs) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Debt [Abstract]
Interest expense and other financing costs	$ 830	$ 955	$ 2,720	$ 2,772
Amortization of deferred financing costs, debt discount and debt premium	47	514	960	1,727
Interest expense	$ 877	$ 1,469	$ 3,680	$ 4,499

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details) - USD ($)	Aug. 01, 2016	Apr. 30, 2018	Sep. 30, 2017	Mar. 31, 2017	Aug. 31, 2015	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Aug. 31, 2018	Aug. 15, 2018	Dec. 31, 2017
Change in fair value of liability									$ 900,000
Change in fair value of warrant						$ (200,000)	$ (300,000)	$ (100,000)	(2,200,000)
Long-term secured term debt fair value						0		0				$ 0
Warrants to purchase								10,671,400
Debt discount						$ 660,000		$ 660,000				1,030,000
IPO price per share								$ 12
Warrants [Member]
Warrants and Rights Outstanding, Term						3 years 10 months 24 days		3 years 10 months 24 days
Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input						0		0
Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input						82.9		82.9
Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input						2.90		2.90
Equity Issued from Credit Agreement [Member]
Fair value of liability												$ 1,200,000
2015 Credit Agreement [Member]
Common units converted to warrants	617,651
Warrants exercised						0		0				0
2015 Credit Agreement [Member] | Equity Issued from Credit Agreement [Member]
Fair value of liability						$ 1,200,000		$ 1,200,000
2015 Credit Agreement, Fifth Amendment [Member]
Strike price											$ 3.30
Debt discount										$ 100,000	$ 700,000
Warrants outstanding											$ 529,413
Other Warrants [Member]
Fair value of liability			$ 1,600,000				1,600,000		1,600,000
Change in fair value of liability							$ (1,100,000)	(700,000)	$ (800,000)
Strike price				$ 4.50
Warrants reclassified from liabilities to equity								$ 22,800,000
Warrants to purchase				$ 2,707,138
Warrants exercised		119,047
Proceeds from warrants exercises		$ 500,000
Warrants expired		2,588,091
Secured Term Debt [Member] | 2015 Credit Agreement [Member]
Strike price						$ 10.20		$ 10.20
Secured Term Debt [Member] | Class A Warrants [Member] | 2015 Credit Agreement [Member]
Warrants to purchase					$ 6,300,000			$ 6,300,000
Strike price, percent for calculation					85.00%
Loss on extinguishment of debt					$ 900,000			900,000
Debt discount					$ 5,400,000	$ 5,400,000		$ 5,400,000
Debt discount amortization term					3 years
2017 Public Offering [Member]
Warrants issued			10,710,000
Strike price			$ 3.35				$ 3.35		$ 3.35
Warrant exercise price term			5 years

Financial Instruments (Fair Val

Financial Instruments (Fair Values of Financial Instruments) (Details) - Significant Other Observable Inputs (Level 2) [Member] - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Total financial instruments	$ 1,247	$ 1,952
Warrants [Member]
Total financial instruments	$ 1,247	$ 1,952

Financial Instruments (Rollforw

Financial Instruments (Rollforward of Level 2 Investments) (Details) - Significant Other Observable Inputs (Level 2) [Member] - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Balance	$ 1,952	$ 3,305
Fair value of warrants modified in the Amendment	111	(908)
Issuance of warrants in private placement		1,651
Change in fair value of financial instruments	(802)	(2,096)
Exercise of warrants recorded as liability	(14)
Balance	$ 1,247	$ 1,952

Financial Instruments (Warrants

Financial Instruments (Warrants Outstanding) (Details)	9 Months Ended
	Sep. 30, 2018$ / sharesshares
Financial Instruments [Abstract]
Warrants, Outstanding | shares	14,722,790
Warrants, Granted | shares
Warrants, Exercised | shares	(134,847)
Warrants, Forfeited | shares	(2,588,091)
Warrants, Outstanding | shares	11,999,852
Warrants, Weighted Average Exercise Price, Outstanding | $ / shares	$ 5.70
Warrants, Weighted Average Exercise Price, Granted | $ / shares
Warrant, Weighted Average Exercise Price, Exercised | $ / shares	4.21
Warrants, Weighted Average Exercise Price, Forfeited | $ / shares	4.50
Warrants, Weighted Average Exercise Price, Outstanding | $ / shares	$ 5.97

Inventories (Narrative) (Detail

Inventories (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Reserve for expirable inventory	$ 3,500		$ 3,500		$ 4,800
Expensed inventory	20	$ 933	265	$ 1,676
Work-in-process inventory	1,032		1,032		80
KD034 [Member]
Work-in-process inventory	$ 1,000		$ 1,000		$ 100

Inventories (Schedule of Invent

Inventories (Schedule of Inventories) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
Inventories [Abstract]
Work-in-process	$ 1,032		$ 80
Finished goods, net	31		121
Total inventories	$ 1,063	$ 201	$ 201

Fixed Assets (Narrative) (Detai

Fixed Assets (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Fixed Assets [Abstract]
Depreciation and amortization of fixed assets	$ 400	$ 500		$ 1,105	$ 1,389
Unamortized computer software costs	600			600		$ 200
Amortization of computer software costs	$ 200	$ 200		$ 100	$ 500
Fully depreciated assets disposed of			$ 2,100

Fixed Assets (Fixed Assets) (De

Fixed Assets (Fixed Assets) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Jan. 01, 2018	Dec. 31, 2017
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 18,783		$ 17,943
Less accumulated depreciation and amortization	(14,756)		(13,651)
Fixed assets, net	4,027	$ 4,292	4,292
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	10,187		10,120
Office Equipment and Furniture [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	1,529		1,488
Machinery and Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	3,242		2,765
Software [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	3,624		3,162
Construction-in-progress [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 201		$ 408
Minimum [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful Lives (Years)	4 years
Minimum [Member] | Office Equipment and Furniture [Member]
Property, Plant and Equipment [Line Items]
Useful Lives (Years)	3 years
Minimum [Member] | Machinery and Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful Lives (Years)	3 years
Minimum [Member] | Software [Member]
Property, Plant and Equipment [Line Items]
Useful Lives (Years)	1 year
Maximum [Member] | Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful Lives (Years)	8 years
Maximum [Member] | Office Equipment and Furniture [Member]
Property, Plant and Equipment [Line Items]
Useful Lives (Years)	15 years
Maximum [Member] | Machinery and Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful Lives (Years)	15 years
Maximum [Member] | Software [Member]
Property, Plant and Equipment [Line Items]
Useful Lives (Years)	5 years

Goodwill (Narrative) (Details)

Goodwill (Narrative) (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Goodwill [Abstract]
Change in goodwill	$ 0	$ 0

Investment in MeiraGTx (Narrati

Investment in MeiraGTx (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 12, 2018	Sep. 30, 2018	Jun. 30, 2018	Apr. 30, 2015	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Oct. 31, 2018	Dec. 31, 2017	Jun. 30, 2015
Common Stock, Shares, Outstanding		113,101,776			113,101,776		113,101,776			78,643,954
Unrealized gain on equity securities					$ 7,564		$ 48,072
Equity securities fair value		$ 48,072			48,072		48,072
Accounts receivable, net		972			972		972			$ 325
MeiraGTx Ltd. [Member]
Equity method investment, fair value			$ 48,100
Stock issued, shares	5,000,000
Common Stock, Shares, Outstanding	27,184,132
Sale of Stock, Price Per Share	$ 15
Ownership percentage			13.00%
Unrealized gain on equity securities			$ 40,500
Remaining payments on lease											$ 700
License Agreement, MeiraGTx Ltd. [Member]
Service revenue to license					100	$ 100	400	$ 400
Cash payments for service revenue							1,300	300
Accounts receivable, net										$ 900
MeiraGTx Ltd. [Member]
Equity method investment, ownership percentage				48.00%
Equity method investment, fair value				$ 24,000
Equity method investment, gain based on the fair value				$ 24,000
Unrealized gain on equity securities		$ 7,600			$ 48,100
Equity method investment, gross profit (loss)						$ (1,800)	$ (1,200)	$ (7,500)
Lease period							5 years
Subsequent Event [Member] | MeiraGTx Ltd. [Member]
Remaining payments on lease									$ 47

License Agreements (Narrative)

License Agreements (Narrative) (Details) - USD ($)	Sep. 13, 2012	Jun. 30, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Jan. 01, 2018	Dec. 31, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Cost of sales and write-down of inventory			$ 79,000	$ 1,210,000	$ 626,000	$ 2,786,000
Accounts receivable, net			972,000		972,000			$ 325,000
Cost method investment			2,300,000		2,300,000		$ 3,542,000	3,542,000
Loss on equity method investment				(1,750,000)	(1,242,000)	(7,479,000)
Accrued expenses			9,514,000		9,514,000			$ 8,577,000
License Agreement, Dyax Corp. [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License revenue	$ 500,000
License Agreement, Limited Liability Company Oncon [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contingent milestone payments			0		0
License revenue		$ 800,000	0	$ 0	0	$ 0
Accrued expenses			$ 800,000		$ 800,000

Share-based Compensation (Narra

Share-based Compensation (Narrative) (Details)	Apr. 03, 2018$ / sharesshares	Oct. 31, 2018shares	Apr. 30, 2018shares	Oct. 31, 2017shares	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	Sep. 30, 2018USD ($)item$ / sharesshares	Sep. 30, 2017USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Jan. 01, 2018shares
Performance Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense | $					$ 2,900,000		$ 2,900,000
Weighted average period for recognition of compensation expense							1 year 7 months 6 days
Share based compensation, options granted	1,597,500								0
Weighted average exercise price of options granted during the period (per share) | $ / shares	$ 4.06						$ 2.71
Share-based compensation, options outstanding, weighted average remaining contractual term (years)							9 years 6 months
Options Outstanding, Units, Exercised							0
Expected dividend yield							0.00%
Expected life							6 years
Risk-free interest rate							2.67%
Volatility							74.50%
Number of performance goals | item							3
Performance period							3 years
Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, options granted							280,924	285,000
Weighted average exercise price of options granted during the period (per share) | $ / shares							$ 4.62	$ 4.11
Share-based compensation, options outstanding, weighted average remaining contractual term (years)							8 years 29 days
Share based compensation, options granted, aggregate intrinsic value | $
Options Outstanding, Units, Exercised
Weighted average grant date fair value of options granted during the period (per share) | $ / shares							$ 2.20	$ 2.62
Expected dividend yield							0.00%	0.00%
Stock Appreciation Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense | $					1,800,000		$ 1,800,000		$ 2,500,000
Weighted average period for recognition of compensation expense							2 years 2 months 12 days		2 years 10 months 24 days
Share based compensation, options granted									1,040,000
Weighted average exercise price of options granted during the period (per share) | $ / shares									$ 3.64
Share-based compensation, options outstanding, weighted average remaining contractual term (years)									9 years 2 months 12 days
Share based compensation, options granted, aggregate intrinsic value | $					0		$ 0
Options Outstanding, Units, Exercised							0
Employees and Director [Member] | Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, options granted							280,924
Weighted average exercise price of options granted during the period (per share) | $ / shares							$ 4.62
Tranche One [Member] | Performance Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of options granted upon reaching goal	33.33%
Tranche Two [Member] | Performance Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of options granted upon reaching goal	66.66%
2016 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Increase in authorized shares as a percentage of common stock issued							4.00%
Shares authorized for issuance									8,523,147	11,668,905
Unrecognized compensation expense | $					6,200,000		$ 6,200,000		$ 13,300,000
Weighted average period for recognition of compensation expense							1 year 8 months 12 days		1 year 10 months 24 days
Share based compensation, options granted							8,115,927
Weighted average exercise price of options granted during the period (per share) | $ / shares							$ 7.06
Stock compensation expense | $					$ 2,800,000	$ 13,200,000	$ 8,400,000	$ 10,600,000
2016 Equity Incentive Plan [Member] | Stock Appreciation Rights [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, options granted									0
2014 Long-Term Incentive Plan (“LTIP”) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity instruments granted							9,750		9,750
Equity instruments base price | $ / shares							$ 6
Equity instrument payable, common stock value percent above grant price							333.00%
Equity instrument payable, common stock value | $ / shares							$ 20
2016 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized for issuance					2,551,180		2,551,180		1,801,180
Share based compensation, options granted			22,958	10,594
Stock compensation expense | $							$ 0	$ 0
Class A [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unit price | $ / shares					$ 3.34		$ 3.34
Minimum [Member] | Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life							5 years 6 months	5 years 6 months
Risk-free interest rate							2.44%	1.87%
Maximum [Member] | Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life							6 years	5 years 9 months
Risk-free interest rate							2.84%	2.00%
Subsequent Event [Member] | 2016 Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation, options granted		29,041

Share-based Compensation (Stock

Share-based Compensation (Stock Options Outstanding) (Details) - Options [Member] - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Units, Beginning Balance	8,496,872
Options Outstanding, Units, Granted	280,924	285,000
Options Outstanding, Units, Exercised
Options Outstanding, Units, Forfeited	(661,869)
Options Outstanding, Units, Ending Balance	8,115,927		8,496,872
Options Vested and Exercisable, Units	4,271,886
Options Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 6.96
Options Outstanding, Weighted Average Exercise Price, Granted	4.62	$ 4.11
Options Outstanding, Weighted Average Exercise Price, Exercised
Options Outstanding, Weighted Average Exercise Price, Forfeited	4.78
Options Outstanding, Weighted Average Exercise Price, Ending Balance	7.06		$ 6.96
Options Vested and Exercisable, Weighted Average Exercise Price	$ 9.69
Options Outstanding, Weighted Average Remaining Contractual Term (years)	8 years 29 days
Options Vested and Exercisable, Weighted Average Remaining Contractual Term (years)	7 years 4 months 13 days		8 years 9 months 29 days
Options Outstanding, Aggregate Intrinsic Value

Share-based Compensation (Weigh

Share-based Compensation (Weighted-average Fair Value of Stock Option Awards Granted) (Details) - Options [Member] - $ / shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value of grants	$ 2.20	$ 2.62
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	72.94%	74.48%
Risk-free interest rate	2.44%	1.87%
Expected life	5 years 6 months	5 years 6 months
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	75.14%	74.70%
Risk-free interest rate	2.84%	2.00%
Expected life	6 years	5 years 9 months

Accrued Expenses (Narrative) (D

Accrued Expenses (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2014	Sep. 30, 2018
Short-Term Accrued Expenses [Line Items]
Severance cost	$ 1,122		$ 569
Accrued expenses	8,577		9,514
Other long term liabilities	247		69
Deferred revenue, current	4,400
Research and development	1,915		3,229
Board of Directors Chairman [Member]
Short-Term Accrued Expenses [Line Items]
Severance expense	1,200
Accrued expenses	1,000		400
Other long term liabilities	200
Class E Redeemable Convertible Units [Member]
Short-Term Accrued Expenses [Line Items]
Gross proceeds from issuance of redeemable convertible units		$ 40,400
Net proceeds from issuance of redeemable convertible units		37,300
Payments of transition costs		$ 3,100
Stock issued, shares		3,514,859
Third Party Investors [Member] | 2014 Stock Issuance [Member] | Class E Redeemable Convertible Units [Member]
Short-Term Accrued Expenses [Line Items]
Accrued liabilities current, commissions payable	$ 2,400		$ 2,400

Accrued Expenses (Short-term Ac

Accrued Expenses (Short-term Accrued Expenses) (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Accrued Expenses [Abstract]
Commission payable	$ 2,395	$ 2,395
Compensation and benefits	408	758
Severance	569	1,122
Research and development	3,229	1,915
Other	2,913	2,387
Total accrued expenses	$ 9,514	$ 8,577

Commitments (Narrative) (Detail

Commitments (Narrative) (Details) $ in Millions	Sep. 30, 2018USD ($)
Future Discretionary Clinical Developments and Regulatory Agency Actions [Member]
Commitments [Line Items]
Additional contingent milestone payments	$ 215.9

Contingencies (Narrative) (Deta

Contingencies (Narrative) (Details) - USD ($) $ in Millions	Sep. 06, 2016	Jul. 25, 2016
The Glodek Litigation [Member]
Loss Contingencies [Line Items]
Claim amount	$ 4	$ 2.8

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details)	Dec. 31, 2016
Kadmon I [Member]
Related Party Transaction [Line Items]
Ownership percentage	12.10%

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Income Tax Disclosure [Line Items]
Change in deferred tax liability	$ 0	$ 0	$ 600,000	$ 0
Income tax expense (benefit)			$ (562,000)	316,000
U.S. federal corporate tax rate			21.00%		35.00%
Revenues	372,000	2,277,000	$ 1,164,000	10,800,000
License Agreement, Jinghua [Member]
Income Tax Disclosure [Line Items]
Income tax expense (benefit)	$ 0	$ 0	$ 0	300,000
Revenues				$ 2,000,000

Uncategorized Items - kdmn-2018

Label	Element	Value
Restricted Cash and Cash Equivalents	us-gaap_RestrictedCashAndCashEquivalents	$ 2,116,000
Restricted Cash and Cash Equivalents	us-gaap_RestrictedCashAndCashEquivalents	$ 2,116,000